<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2901244808
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Gardasil 9
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HUMAN PAPILLOMAVIRUS TYPE 6 L1,HUMAN PAPILLOMAVIRUS TYPE 11 L1,HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN,HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN,Human Papillomavirus Type 31 L1 protein,Human Papillomavirus Type 33 L1 protein,Human Papillomavirus Type 45 L1 protein,Human Papillomavirus Type 52 L1 protein,Human Papillomavirus Type 58 L1 protein
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30,40,60,40,20,20,20,20,20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        605
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Baxter Pharmaceutical Solutions, LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Baxter Pharmaceutical Solutions, LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP AND DOHME LLC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07BM03-papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>In girls and women 9 through 45 years of age, Gardasil&nbsp;9 helps protect against:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cervical cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vulvar and vaginal cancers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anal cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain head and neck cancers, such as throat and back of mouth cancers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Precancerous cervical, vulvar, vaginal and anal lesions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genital warts</p><p>&nbsp;</p><p>In boys and men 9 through 45 years of age, Gardasil&nbsp;9 helps protect against:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anal cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain head and neck cancers, such as throat and back of mouth cancers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Precancerous anal lesions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genital warts</p><p><strong>&nbsp;</strong></p><p>These diseases may have many causes, including HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Gardasil&nbsp;9 only protects against diseases caused by these nine types of HPV.</p><p>&nbsp;</p><p>People cannot get HPV or any of these diseases from Gardasil&nbsp;9.</p><p>&nbsp;</p><p><strong>Gardasil&nbsp;9:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Does not remove the need for screening for cervical, vulvar, vaginal, anal, and certain head and neck cancers, such as throat and back of mouth cancers as recommended by a doctor; women should still get routine cervical cancer screening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Does not protect the person getting Gardasil&nbsp;9 from a disease that is caused by other types of HPV, other viruses or bacteria.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Does not treat HPV infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Does not protect the person getting Gardasil&nbsp;9 from HPV types that he/she may already have.</p><p>&nbsp;</p><p>Gardasil&nbsp;9 may not fully protect each person who gets it.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not receive Gardasil&nbsp;9 if you or your child has had an allergic reaction to</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A previous dose of GARDASIL&nbsp;9</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A previous dose of GARDASIL<sup>&reg;</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yeast (severe allergic reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amorphous aluminum hydroxyphosphate sulfate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Polysorbate 80</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Tell the doctor, pharmacist or nurse if you or your child (the person getting Gardasil&nbsp;9):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are pregnant or planning to get pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have immune problems, like HIV or cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take medicines that affect the immune system.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have a fever over 100&deg;F (37.8&deg;C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Might have had an allergic reaction to a previous dose of Gardasil&nbsp;9 or Gardasil.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take any medicines, even those you can buy over the counter.</p><p><strong>&nbsp;</strong></p><p>The health care professional will help decide if you or your child should get the vaccine.</p><p>&nbsp;</p><p><strong>Other medicines and Gardasil&nbsp;9</strong></p><p>Gardasil&nbsp;9 can be given at the same time as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adacel [Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)]</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant, think that you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before you receive this vaccine.</p><p>&nbsp;</p><p>Gardasil&nbsp;9 may be given to women who are breast-feeding or intend to breast-feed.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Gardasil&nbsp;9 may slightly and temporarily affect the ability to drive or use machines (see section&nbsp;4 &ldquo;Possible side effects&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gardasil&nbsp;9 is a shot that is usually given in the arm muscle. Gardasil&nbsp;9 may be given as 2 or 3 shots.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:642px"><tbody><tr><td style="vertical-align:top"><p><strong>For persons who are</strong></p></td><td style="vertical-align:top"><p><strong>You will need</strong></p></td><td style="vertical-align:top"><p><strong>Given as </strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>9 through 14 years old</p></td><td style="vertical-align:top"><p>2-shots*</p></td><td style="vertical-align:top"><p>Dose 1: first shot</p><p>Dose 2: second shot given between 6 and 12 months after the first shot</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;or 3-shots**</p></td><td style="vertical-align:top"><p>Dose 1: first shot</p><p>Dose 2: second shot given 2 months after the first shot</p><p>Dose 3: third shot given 6 months after the first shot</p></td></tr><tr><td style="vertical-align:top"><p>15 through 45 years old</p></td><td style="vertical-align:top"><p>3-shots</p></td><td style="vertical-align:top"><p>Dose 1: first shot</p><p>Dose 2: second shot given 2 months after the first shot</p><p>Dose 3: third shot given 6 months after the first shot</p></td></tr></tbody></table><p>*If the second shot is given earlier than 5 months after the first shot, you will need to get a third shot at least 4 months after the second shot was given.</p><p>**The need to use a 3-dose schedule instead of a 2-dose schedule will be determined by your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p>Make sure that you or your child gets all doses recommended by your doctor, pharmacist or nurse so that you or your child gets the best protection. If the person getting Gardasil&nbsp;9 misses a dose, tell the doctor, pharmacist or nurse and they will decide when to give the missed dose. It is important that you follow the instructions of your doctor, pharmacist or nurse regarding return visits for the follow-up doses.</p><p>&nbsp;</p><p>Fainting can happen after getting an HPV vaccine. Sometimes people who faint can fall and hurt themselves. For this reason, the doctor, pharmacist or nurse may ask the person getting Gardasil&nbsp;9 to sit or lie down for 15 minutes after getting the vaccine. Some people who faint might shake or become stiff. The doctor, pharmacist or nurse may need to treat the person getting Gardasil&nbsp;9.</p><p>&nbsp;</p><p>If you have already gotten Gardasil, talk to your doctor, pharmacist or nurse to see if Gardasil&nbsp;9 is right for you.</p><p>&nbsp;</p><p>If you have any further questions on the use of this vaccine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The most common side effects seen with Gardasil&nbsp;9 are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, swelling, redness, itching, bruising, bleeding, and a lump where you got the shot</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat</p><p>&nbsp;</p><p>Studies show that there was more swelling where the shot was given when Gardasil&nbsp;9 was given at the same time as Menactra and/or Adacel.</p><p>&nbsp;</p><p>Tell the doctor, pharmacist or nursel if you have any of these problems because these may be signs of an allergic reaction:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wheezing (bronchospasm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&nbsp;</p><p>Additional side effects that have been reported during general use for Gardasil&nbsp;9 are shown below. Side effects reported during the general use of Gardasil are also shown below. Gardasil side effects are reported as they may be relevant to Gardasil&nbsp;9 since the vaccines are similar in composition.</p><p>&nbsp;</p><p><u>Gardasil&nbsp;9</u></p><ul><li>vomiting</li><li>hives</li></ul><p><u>&nbsp;</u></p><p>Additionally, these side effects have been seen with the general use of Gardasil.</p><p>&nbsp;</p><p><u>Gardasil</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen glands (neck, armpit, or groin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual tiredness, weakness, or confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leg pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aching muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bad stomach ache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding or bruising more easily than normal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin infection</p><p>You should contact your doctor, pharmacist or nurse right away if you get any symptoms that bother you.</p><p>&nbsp;</p><p>For a more complete list of side effects, ask the doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance Centre (NPC), SFDA. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this vaccine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this vaccine after the expiry date which is stated on the carton and syringe label after EXP.</p><p>&nbsp;</p><p>Store in a refrigerator (2&nbsp;&ordm;C&nbsp;&ndash;&nbsp;8&nbsp;&ordm;C). Do not freeze. Protect from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>GARDASIL&nbsp;9 contains:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proteins of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amorphous aluminum hydroxyphosphate sulfate adjuvant (500 &mu;g aluminum content)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium chloride (9.56 mg)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; L-histidine (0.78 mg)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Polysorbate 80 (50 &mu;g)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium borate (35 &mu;g)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water for injection (QS)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                1 dose of Gardasil 9 contains 0.5 ml.

After thorough agitation, it is a white, cloudy liquid.

Gardasil 9 is available in pack of 1 pre-filled syringe.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder &amp; Manufacturer:</strong></p><p>Merck Sharp &amp; Dohme LLC</p><p>770 Sumneytown Pike,</p><p>West Point, Pennsylvania 19486, USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 March 2024

To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to Instructions are dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.
Council of Arab Health Ministers  
 Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food & Drug Authority. 






------------------------------------------------------------------------------------------------------------------------

The following information is intended for healthcare professionals only:

Prefilled Syringe Use 
This package contains one needle. 
Shake well before use. 
After thorough agitation, GARDASIL 9 is a white, cloudy liquid.
Attach a needle by twisting in a clockwise direction until the needle fits securely on the syringe. 
Administer the entire dose as per standard protocol. Discard syringe after use.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">قارداسيل 9 هو لقاح (حُقنة) يُعطى للأفراد الذين تتراوح أعمارهم بين 9 &ndash; 45 عامًا للمساعدة في الحماية من الأمراض التي تُسببها بعض أنواع فيروس الورم الحليمي البشري (إش بي في HPV).</p><p dir="RTL"><strong>ما الأمراض التي يمكن أن يساعد قارداسيل 9 في الحماية منها؟</strong></p><p dir="RTL">لدى الفتيات والنساء ممن تتراوح أعمارهن من 9 إلى 45 عامًا، يساعد قارداسيل 9 في الحماية من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان عنق الرحم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطانات المهبل والفرج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الشرج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع السرطان في الرأس والرقبة، مثل سرطان الحلق والجزء الخلفي من الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آفات عنق الرحم والفرج والمهبل والشرج القابلة للتسرطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الثآليل التناسلية</p><p dir="RTL">&nbsp;</p><p dir="RTL">لدى الأولاد والرجال الذين تتراوح أعمارهم بين 9 و 45 عامًا، يساعد قارداسيل 9 على الحماية من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الشرج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع السرطان في الرأس والرقبة، مثل سرطان الحلق والجزء الخلفي من الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآفات الشرجية القابلة للتسرطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الثآليل التناسلية</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تنجم هذه الأمراض عن عدة أسباب ، بما فيها الأنواع التالية من فيروس الورم الحليمي البشري 6 و 11 و 16 و 18 و 31 و 33 و 45 و 52 و 58. يقي قارداسيل من الأمراض التي تُسببها الأنواع التسعة الآنفة الذكر من فيروس الورم الحليمي البشري.</p><p dir="RTL">لا يُسبّب قارداسيل 9 العدوى بأيّ نوع من أنواع فيروس الورم الحليمي البشري.</p><p dir="RTL"><strong>لقاح قارداسيل &nbsp;&nbsp;9&nbsp; :</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يلغي الحاجة إلى إجراء فحص سرطان عنق الرحم والفرج والمهبل والشرج وبعض سرطانات الرأس والرقبة، مثل سرطان الحلق والجزء الخلفي من الفم على النحو الموصى به من قبل الطبيب ؛ كما يجب أن تستمر النساء في الخضوع للفحص الروتيني لسرطان عنق الرحم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلقي قارداسيل 9 لا يحمي من الإصابة بمرض تسببه أنواع أخرى من فيروس الورم الحليمي البشري أو الفيروسات أو البكتيريا الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يعالج عدوى فيروس الورم الحليمي البشري.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قارداسيل 9 لا يحمي الشخص الذي تلقاه من أنواع فيروس الورم الحليمي البشري المصاب بها بالفعل.</p><p dir="RTL">قد لا يوفر قارداسيل 9 الحماية التامة من الإصابة بالعدوى لكل شخص يتلقاه. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتلقَ قارداسيل 9 إذا </strong>كان لديك أو لدى طفلك رد فعل تحسّسي نحو أيّ مما يلي <strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة سابقة من قارداسيل 9</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة سابقة من قارداسيل<sup>&reg;</sup></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخميرة (رد فعل تحسّسي شديد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبريتات هيدروكسي فوسفات الألومنيوم غير المتبلورة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوليسوربات 80</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><br />أخبر طبيبك أو الصيدلي أو الممرضة قبل التطعيم إذا كنت أنت أو طفلك (الشخص الذي سيتلقّى قارداسيل ):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاملًا أو تخططين للحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل مناعية ، مثل عدوى فيروس نقص المناعة البشري أو السرطان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول الأدوية التي تؤثر على جهاز المناعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك حمى تزيد عن 37.8 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تعرّضت لرد فعل تحسسي لجرعة سابقة من قارداسيل 9 أو قارداسيل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أي أدوية، بما في ذلك تلك التي يمكنك شراءها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيساعدك أخصائي الرعاية الصحية في تحديد ما إذا كان ينبغي لك أو لطفلك الحصول على اللقاح.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى وقارداسيل 9</strong><br />يمكن إعطاء قارداسيل 9 في الوقت نفسه مع :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميناكترا [لقاح المكورات السحائية (المجموعات A و C و Y و W-135) لقاح متعدد السكاريد مُقترن بذوفان الدفتيريا]</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أداسيل [ذوفان التيتانوس، لقاح الدفتيريا المخفّف، والسعال الديكي اللاخلوي الممتز (Tdap)]<br />&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">استشيري طبيبك أو الصيدلي أو الممرضة قبل تلقّي هذا اللّقاح إذا كنت حاملًا، تعتقدين أنك قد تكونين حاملًا أو تخططين للحمل. &nbsp;&nbsp;<br />يمكن إعطاء قارداسيل 9 للنساء المُرضعات أو اللاتي يعتزمن ممارسة الرضاعة الطبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يؤثر قارداسيل 9 بشكل طفيف ومؤقت على القدرة على القيادة أو استخدام الآلات (انظر القسم 4 &quot;الأعراض الجانبية المحتملة&quot;).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قارداسيل 9 عبارة عن حقنة تُعطى عادة في عضلة الذّراع. يمكن إعطاء قارداسيل 9 &nbsp;حسب جدول زمني مكوّن إمّا من جرعتين أو ثلاث جرعات.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:642px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الفئة العمرية</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>عدد الحقن</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجدول الزمني للجرعات </strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p dir="RTL">من 9 إلى 14 سنة</p></td><td style="vertical-align:top"><p dir="RTL">2 حقنة*</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة 1: الحقنة الأولى</p><p dir="RTL">الجرعة 2: الحقنة الثانية تُعطى بين 6 و 12 شهرا بعد الجرعة الأولى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;أو 3 حُقن**</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة 1: الحقنة الأولى</p><p dir="RTL">الجرعة 2: الحقنة الثانية تُعطى بعد شهرين من الحقنة الأولى</p><p dir="RTL">الجرعة 3: الجرعة الثالثة تُعطى بعد 6 أشهر من الحقنة الأولى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">من 15 إلى 45 سنة</p></td><td style="vertical-align:top"><p dir="RTL">3 حقن</p></td><td style="vertical-align:top"><p dir="RTL">الجرعة 1: الحقنة الأولى</p><p dir="RTL">الجرعة 2: الحقنة الثانية تُعطى بعد شهرين من الحقنة الأولى</p><p dir="RTL">الجرعة 3: الحقنة الثالثة تُعطى بعد 6 أشهر من الحقنة الأولى</p></td></tr></tbody></table><p dir="RTL">* إذا أُعطيت الحقنة الثانية قبل انقضاء 5 أشهر من تلقي الحقنة الأولى، فستحتاج إلى تلقّي حقنة ثالثة بعد 4 أشهر على الأقل من إعطاء الحقنة الثانية.</p><p dir="RTL">** سيُقرّر طبيبك أو الصيدلي أو الممرضة اتباع إما جدول زمني مكون من 3 جرعات أو جدول زمني من جرعتين.&nbsp;</p><p>&nbsp;</p><p dir="RTL">تأكد من حصولك أنت أو طفلك على جميع الجرعات الموصى بها من قبل طبيبك أو الصيدلي أو الممرضة حتى تحصل أنت أو طفلك على أفضل حماية. إذا فاتتك إحدى الجرعات، أخبر الطبيب أو الصيدلي أو الممرضة وسيقرر موعد إعطاء الجرعة الفائتة. من المهم أن تتبع تعليمات الطبيب أو الممرضة فيما يتعلق بزيارات المتابعة لتلقي الجرعات المُجدولة.</p><p dir="RTL">يمكن أن يحدث إغماء بعد تلقي لقاح فيروس الورم الحليمي البشري. قد يسقط الشخص الذي يتعرّض للإغماء ويؤذي نفسه أحيانًا. لهذا السبب، قد يطلب الطبيب أو الصيدلي أو الممرضة من الشخص الذي يتلقّى قارداسيل 9 الجلوس أو الاستلقاء لمدة 15 دقيقة بعد تلقّي اللقاح. كما قد يتعرّض الشخص وهو في حالة الإغماء للارتعاش أو التيبّس. وبالتالي قد يحتاج الشخص الذي يتلقى قارداسيل 9 إلى علاج من قبل الطبيب أو الصيدلي أو الممرضة.</p><p dir="RTL">إذا تلقّيت قارداسيل 9 بالفعل، فتحدث إلى طبيبك أو الصيدلي أو الممرضة لمعرفة ما إذا كان قارداسيل 9&nbsp; مناسبًا لك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا اللقاح ، اسأل طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الأعراض الجانبية الأكثر شيوعًا التي لوحظت مع قارداسيل 9 هي :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم ، تورم ، احمرار، حكّة ، كدمات ، نزيف وكتلة في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع بطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهاب الحلق</p><p dir="RTL">تشير الدراسات إلى حدوث تورم أكبر في موضع الحقن عند إعطاء قارداسيل 9 في الوقت نفسه مع ميناكترا و/أو أداسيل.</p><p>Save translation</p><p dir="RTL">أخبر الطبيب أو الصيدلي أو الممرضة إذا تعرّضت لأي من العلامات التالية لأنها قد تكون علامات لرد فعل تحسسي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صفير (تشنج قصبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p>Translation is too long to be saved</p><p dir="RTL">الأعراض الجانبية الإضافية التي بُلّغ عنها أثناء الاستخدام العام لقارداسيل 9 موضحة أدناه. الأعراض الجانبية التي بُلّغ عنها أثناء الاستخدام العام لـقارداسيل موضحة أدناه أيضًا. أُدرجت الأعراض الجانبية لـقارداسيل لأنها قد تكون ذات صلة بـقارداسيل 9 وذلك لأن اللقاحات متشابهة في التركيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>قارداسيل 9 </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قشعريرة</p><p>Translation is too long to be saved</p><p dir="RTL">بالإضافة إلى ذلك ، لوحظت الأعراض الجانبية التالية مع الاستخدام العام لقارداسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>قارداسيل </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الغدد (الرقبة أو الإبط أو الفخذ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق أو ضعف أو ارتباك غير عادي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بتوعك بشكل عام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الساق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم صدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث نزيف أو كدمات بسهولة أكبر من المعتاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك الاتصال بطبيبك أو الصيدلي أو الممرضة على الفور إذا ظهرت عليك أي أعراض تزعجك. للحصول على قائمة الأعراض الجانبية الكاملة، اسأل الطبيب أو الصيدلي أو الممرضة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong><br />إذا تعرّضت لأي أعراض جانبية، تحدث مع طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. یمکنك أیضا الإبلاغ عن الأعراض الجانبیة مباشرة من خلال المركز الوطني للتيقظ الدوائي، الهيئة العامة للغذاء والدواء السعودية. یمکنك المساعدة في توفیر المزید من المعلومات حول سلامة ھذا الدواء من خلال الإبلاغ عن الأعراض الجانبیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا اللقاح بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا اللقاح بعد تاريخ انتهاء الصالحية المدوّن على ملصق القارورة والكرتون الخارجي (بعدEXP).<br />يُحفظ في الثلاجة على درجة حرارة 2 إلى 8 درجات مئوية. لا يُجمد. يُحفظ بعيدًا عن الضوء.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي قارداسيل 9</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروتينات أنواع فيروس الورم الحليمي البشري 6 و 11 و 16 و 18 و 31 و 33 و 45 و 52 و 58</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مساعد كبريتات هيدروكسي فوسفات الألومنيوم غير المتبلورة (500 ميكروغرام محتوى الألومنيوم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلوريد الصوديوم (9.56 ملغ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إل-هيستيدين (0.78 ملغ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوليسوربات 80 (50 ميكروغرام)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بورات الصوديوم (35 ميكروغرام)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الماء المُخصّص للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشكل الصيدلاني لقارداسيل 9 ووصفه وحجم عبوته &nbsp;</strong><br />تتكون الجرعة الواحدة من لقاح قارداسيل 9 من 0,5 مل.</p><p dir="RTL">يظهر قارداسيل 9 عل شكل سائل مُعكّر أبيض بعد الرجّ الجيد.</p><p dir="RTL">يتوفّر قارداسيل في عُلب تحتوي كل منها على مِحقنة واحدة مُسبقة التعبئة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق و الشركة الصانعة:</strong></p><p dir="RTL">ميرك شارب أند دوهم ذات مسوؤلية محدودة<br />770 سومنيتاون بايك، ويست بوينت، بنسلفانيا 19486، الولايات المتحدة الأمريكية</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ {مارس 2024}
للإبلاغ عن أي أعراض جانبية:
•	المملكة العربية السعودية: 
المركز الوطني للتيقظ الدوائي (NPC) :
مركز اتصال الهيئة العامة للغذاء والدواء: 19999
البريد الإلكتروني: npc.drug@sfda.gov.sa
الموقع الإلكتروني: https://ade.sfda.gov.sa
•	دول مجلس التعاون الخليجي الأخرى: 
يرجى الاتصال بالسلطة المختصة ذات الصلة.


هذا المستحضر هو دواء
-	الدواء مستحضر يؤثر على صحتك وتناوله خلافًا للتعليمات يعرضك للخطر.
-	اتبع بدقة وصفة الطبيب وطريقة الاستعمال وتعليمات الصيدلي الذى صرفها.
-	الطبيب والصيدلي هما الخبيران في الأدوية وفوائدها ومخاطرها.
-	لا تقطع مدة العلاج المحددة لك بنفسك.
-	لا تكرر العلاج بدون استشارة الطبيب.
-	احفظ جميع الأدوية بعيدا عن متناول الأطفال.
مجلس وزراء الصحة العرب
واتحاد الصيادلة العرب
نشرة معلومات المريض هذه معتمدة من الهيئة العامة للغذاء والدواء بالمملكة العربية السعودية.
-------------------------------------------------- -----------
المعلومات التالية موجهة لأخصائيي الرعاية الصحية فقط:
استخدام المِحقنة مُسبقة التعبئة 
تحتوي هذه العبوة على إبرة واحدة.
يُرج جيدًا قبل الاستخدام.
بعد الرجّ الجيد ، يظهر قارداسيل على شكل سائل أبيض عكِر.
قم بتوصيل الإبرة عن طريق لفها في اتجاه عقارب الساعة حتى تثبت الإبرة بإحكام على المحقنة.
قم بحقن الجرعة بأكملها وفقًا للبروتوكول القياسي المُتبع. تخلّص من المحقنة بعد الاستخدام.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gardasil® 9 suspension for intramuscular injection.
Human Papillomavirus 9 valent Vaccine (Recombinant)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein.

The L1 proteins in the form of virus-like particles are adsorbed on preformed aluminum-containing adjuvant (Amorphous Aluminum Hydroxyphosphate Sulfate or AAHS).

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for intramuscular injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Girls and Women</strong></p><p>Gardasil<sup>&reg; </sup>9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genital warts (condyloma acuminata) caused by HPV types 6 and 11</p><p>And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cervical intraepithelial neoplasia (CIN) grade 2/3 and cervical adenocarcinoma <em>in situ</em> (AIS)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cervical intraepithelial neoplasia (CIN) grade 1</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3</p><p><strong>Boys and Men</strong></p><p>Gardasil<sup>&reg; </sup>9&nbsp; is indicated in boys and men 9 through 45 years of age for the prevention of the following diseases:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genital warts (condyloma acuminata) caused by HPV types 6 and 11</p><p>And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3</p><p>&nbsp;</p><p>The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease [see Pharmacodynamic Properties (5.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</p><p>&nbsp;</p><p><strong>Limitations of Use and Effectiveness</strong></p><p>Vaccination with Gardasil&nbsp;9 does not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a health care provider.</p><p><em>&nbsp;</em></p><p>Gardasil&nbsp;9 has not been demonstrated to provide protection against disease caused by:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HPV types not covered by the vaccine <em>[see Qualitative and Quantitative Composition (2)]</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HPV types to which a person has previously been exposed through sexual activity.</p><p><em>&nbsp;</em></p><p>Not all vulvar, vaginal, anal, oropharyngeal and other head and neck cancers are caused by HPV, and Gardasil&nbsp;9 protects only against those vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV 16, 18, 31, 33, 45, 52, and 58.</p><p>&nbsp;</p><p>Gardasil&nbsp;9 is not a treatment for external genital lesions; cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers; CIN; VIN; VaIN; or AIN.</p><p>&nbsp;</p><p>Vaccination with Gardasil&nbsp;9 may not result in protection in all vaccine recipients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p><strong>For intramuscular use only</strong></p><p>&nbsp;</p><p>Each dose of Gardasil&nbsp;9 is 0.5-mL.</p><p><u>&nbsp;</u></p><p>Administer Gardasil&nbsp;9 as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Age</p></td><td style="vertical-align:top"><p>Regimen</p></td><td style="vertical-align:top"><p>Schedule</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>9 through 14 years</p></td><td style="vertical-align:top"><p>2-dose</p></td><td style="vertical-align:top"><p>0, 6 to 12 months*</p></td></tr><tr><td style="vertical-align:top"><p>3-dose</p></td><td style="vertical-align:top"><p>0, 2, 6 months</p></td></tr><tr><td style="vertical-align:top"><p>15 through 45 years</p></td><td style="vertical-align:top"><p>3-dose</p></td><td style="vertical-align:top"><p>0, 2, 6 months</p></td></tr></tbody></table><p>*If the second dose is administered earlier than 5 months after the first dose, administer a third dose at least 4 months after the second dose. <em>[See Pharmacodynamic Properties (5.1).]</em></p><p>&nbsp;</p><p>Administration of Gardasil&nbsp;9 in Individuals Who Have Been Previously Vaccinated with Gardasil<sup>&reg;</sup></p><p>Safety and immunogenicity were assessed in individuals who completed a three-dose vaccination series with GARDASIL&nbsp;9 and had previously completed a three-dose vaccination series with GARDASIL <em>[see Undesirable Effects (4.8) and Pharmacodynamic Properties (5.1)]. </em>Studies using a mixed regimen of HPV vaccines to assess interchangeability were not performed for GARDASIL&nbsp;9.</p><p><em>&nbsp;</em></p><p><strong>Pediatric Use</strong></p><p>Safety and effectiveness have not been established in pediatric patients below 9 years of age.</p><p>&nbsp;</p><p><strong>Geriatric Use</strong></p><p>The safety and effectiveness of GARDASIL&nbsp;9<sup> </sup>have not been evaluated in a geriatric population, defined as individuals aged 65 years and over.</p><p><strong>&nbsp;</strong></p><p><strong>Immunocompromised Individuals</strong></p><p>The immunologic response to GARDASIL&nbsp;9 may be diminished in immunocompromised individuals <em>[see Interaction with other medicinal products and other forms of interaction</em><strong> </strong><em>(4.5)]</em>.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not dilute or mix Gardasil&nbsp;9 with other vaccines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake well immediately before use to maintain suspension of the vaccine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use the product if particulates are present or if it appears discolored. After thorough agitation, Gardasil&nbsp;9 is a white cloudy liquid.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer intramuscularly in the deltoid or anterolateral area of the thigh.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Observe patients for 15 minutes after administration <em>[see Special warnings and precautions for use (4.4)].</em></p><p>&nbsp;</p><p>Prefilled Syringe Use</p><p>This package contains one needle. Shake well before use. Attach a needle by twisting in a clockwise direction until the needle fits securely on the syringe. Administer the entire dose as per standard protocol. Discard syringe after use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous 
dose of Gardasil 9 or Gardasil [see Qualitative and Quantitative Composition (2) and Pharmaceutical Particulars (6.1)].
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Syncope</strong></p><p>Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15&nbsp;minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following HPV vaccination. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion by maintaining a supine or Trendelenburg position.</p><p><strong>Managing Allergic Reactions</strong></p><p>Appropriate medical treatment and supervision must be readily available in case of anaphylactic reactions following the administration of Gardasil&nbsp;9.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Use with Systemic Immunosuppressive Medications</strong></p><p>Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Risk Summary</p><p>All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. There are no adequate and well-controlled studies of Gardasil&nbsp;9 &nbsp;in pregnant women. Data from GARDASIL are relevant to GARDASIL 9 because both vaccines are manufactured using the same process and have overlapping compositions. Data were evaluated from pre-licensure studies in which 55 and 62 pregnancies with known outcomes were associated with women inadvertently exposed to GARDASIL and GARDASIL 9, respectively. Pregnancy Exposure Registry data are available from 1640 and 69 prospectively enrolled women with known pregnancy outcomes who were vaccinated with GARDASIL and GARDASIL 9, respectively. Available data do not suggest an increased risk of major birth defects and miscarriage in women who received GARDASIL or GARDASIL 9.</p><p>In one developmental toxicity study, 0.5&nbsp;mL of a vaccine formulation containing between 1 and 1.5 &ndash;fold of each of the 9&nbsp;HPV antigen types was administered to female rats prior to mating and during gestation. In a second study, animals were administered a single human dose (0.5&nbsp;mL) of Gardasil&nbsp; 9 prior to mating, during gestation and during lactation. These animal studies revealed no evidence of harm to the fetus due to Gardasil&nbsp;9</p><p>&nbsp;</p><p>Data</p><p><u>Human Data</u></p><p>In pre-licensure clinical studies of Gardasil&nbsp; 9, women underwent pregnancy testing immediately prior to administration of each dose of Gardasil&nbsp; 9 or control vaccine (Gardasil&nbsp;). Subjects who were determined to be pregnant were instructed to defer vaccination until the end of their pregnancy. Despite this pregnancy screening regimen, some subjects were vaccinated very early in pregnancy before human chorionic gonadotropin (HCG) was detectable. An analysis was conducted to evaluate pregnancy outcomes for pregnancies with onset within 30 days before or after vaccination with Gardasil&nbsp; 9 or Gardasil&nbsp;. Among such pregnancies, there were 62 and 55 with known outcomes (excluding ectopic pregnancies and elective terminations) for Gardasil&nbsp; 9 and Gardasil&nbsp;, respectively, including 44 and 48 live births, respectively. The rates of pregnancies that resulted in a miscarriage were 27.4% (17/62) and 12.7% (7/55) in subjects who received Gardasil&nbsp; 9 or Gardasil&nbsp;, respectively. The rates of live births with major birth defects were 0% (0/44) and 2.1% (1/48) in subjects who received Gardasil&nbsp;9 or Gardasil&nbsp;, respectively.</p><p>&nbsp;</p><p>&nbsp;</p><p>A six-year pregnancy registry for GARDASIL 9 enrolled 185 women who were exposed to GARDASIL 9 within one month prior to the last menstrual period (LMP) or at any time during pregnancy, 180 of whom were prospectively followed. After excluding elective terminations (n=1), ectopic pregnancies (n=0) and those lost to follow-up (n=110), there were 69 pregnancies (including one twin pregnancy) with known outcomes. Of the 69 pregnancies, 5 were in women exposed twice during pregnancy. Therefore, there were 74 exposures to GARDASIL 9 during pregnancy: 3 occurred during the 30 days prior to LMP, 34 during the first trimester, 13 during the second trimester, 19 during the third trimester, and 5 in an unknown trimester. Adverse pregnancy outcomes included 3 miscarriages (all in pregnancy exposures during the first trimester) and 3 major birth defects (one each for pregnancy exposure during the 30 days prior to LMP, first trimester, and second trimester). Women who were exposed twice during pregnancy had 0 miscarriages and 0 major birth defects. These data do not suggest an increased risk of major birth defects and miscarriage in women who received GARDASIL 9.</p><p>&nbsp;</p><p>A five-year pregnancy registry enrolled 2,942 women who were exposed to Gardasil&nbsp; within one month prior to the LMP or at any time during pregnancy, 2,566 of whom were prospectively followed. After excluding elective terminations (n=107), ectopic pregnancies (n=5) and those lost to follow-up (n=814), there were 1,640 pregnancies with known outcomes. Rates of miscarriage and major birth defects were 6.8% of pregnancies (111/1,640) and 2.4% of live born infants (37/1,527), respectively. These rates of assessed outcomes in the prospective population were consistent with estimated background rates.</p><p>&nbsp;</p><p>In two postmarketing studies of Gardasil&nbsp; (one conducted in the U.S., and the other in Nordic countries), pregnancy outcomes among subjects who received Gardasil&nbsp; during pregnancy were evaluated retrospectively. Among the 1,740 pregnancies included in the U.S. study database, outcomes were available to assess the rates of major birth defects and miscarriage. Among the 499 pregnancies included in the Nordic study database, outcomes were available to assess the rates of major birth defects. In both studies, rates of assessed outcomes did not suggest an increased risk with the administration of Gardasil&nbsp;during pregnancy.</p><p>&nbsp;</p><p><u>Animal Data</u></p><p>Developmental toxicity studies were conducted in female rats. In one study, animals were administered 0.5&nbsp;mL of a vaccine formulation containing between 1 and 1.5 &ndash;fold of each of the 9&nbsp;HPV antigen types 5 and 2 weeks prior to mating, and on gestation day 6. In a second study, animals were administered a single human dose (0.5 mL) of Gardasil&nbsp; 9, 5 and 2 weeks prior to mating, on gestation day 6, and on lactation day 7. No adverse effects on pre- and post-weaning development were observed. There were no vaccine-related fetal malformations or variations, or effects on female fertility.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Risk Summary</p><p>Available data are not sufficient to assess the effects of Gardasil&nbsp;9 on the breastfed infant or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for Gardasil&nbsp;9 and any potential adverse effects on the breastfed child from Gardasil&nbsp;9 or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>&nbsp;</p><p>No human data on the effect of Gardasil&nbsp;9 on fertility are available. Animal studies do not indicate harmful effects on fertility [see Preclinical safety data (5.3)].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gardasil&nbsp;9 has no or negligible influence on the ability to drive or use machines. However, some of the effects mentioned under section&nbsp;4.8 &ldquo;Undesirable effects&rdquo; may temporarily affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>A. Summary of the safety profile</u></p><p>&nbsp;</p><p><u>Clinical trials</u></p><p><strong>Clinical Trials Experience</strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p>The safety of Gardasil&nbsp;9 was evaluated in seven clinical studies that included 15,703 individuals who received at least one dose of Gardasil&nbsp; 9 and had safety follow-up. Study 1 and Study 3 also included 7,378 individuals who received at least one dose of Gardasil&nbsp; as a control and had safety follow-up. The vaccines were administered on the day of enrollment and the subsequent doses administered approximately two and six months thereafter. Safety was evaluated using vaccination report card (VRC)-aided surveillance for 14 days after each injection of Gardasil&nbsp; 9 or Gardasil&nbsp;.</p><p>The individuals who were monitored using VRC-aided surveillance included 9,097 girls and women 16 through 26 years of age, 1,394 boys and men 16 through 26 years of age, and 5,212 girls and boys 9 through 15 years of age (3,436 girls and 1,776 boys) at enrollment who received Gardasil&nbsp; 9; and 7,078 girls and women 16 through 26 years of age and 300 girls 9 through 15 years of age at enrollment who received Gardasil&nbsp;. The race distribution of the integrated safety population for Gardasil&nbsp; 9 was similar between girls and women 16 through 26 years of age (56.8% White; 25.2% Other Races or Multiracial; 14.1% Asian; 3.9% Black), girls and boys 9 through 15 years of age (62.0% White; 19.2% Other Races or Multiracial; 13.5% Asian; 5.4% Black), and boys and men 16 through 26 years of age (62.1% White; 22.6% Other Races or Multiracial; 9.8% Asian; 5.5% Black). The safety of Gardasil&nbsp; 9 was compared directly to the safety of Gardasil&nbsp; in two studies (Study 1 and Study 3) for which the overall race distribution of the Gardasil&nbsp; cohorts (57.0% White; 26.3% Other Races or Multiracial; 13.6% Asian; 3.2% Black) was similar to that of the Gardasil&nbsp; 9 cohorts.</p><p>&nbsp;</p><p>Safety of Gardasil&nbsp; 9 in women 27 through 45 years of age was evaluated in a clinical trial comparing 640 women 27 through 45 years of age and 570 girls and women 16 through 26 years of age. The race distribution was similar between women 27 through 45 years of age (97.7% White, 1.6% Asian, 0.3% Other or Multiracial, 0.5% Black) and girls and women 16 through 26 years of age (94.6% White, 3.0% Asian, 1.6% Other or Multiracial, 0.9% Black).</p><p>&nbsp;</p><p>Safety of Gardasil&nbsp; 9 in men 27 through 45 years of age is inferred from the safety data of Gardasil&nbsp; 9 in boys and men 9 through 26 years of age and girls and women 9 through 45 years of age and Gardasil&nbsp; in individuals 9 through 45 years of age.</p><p>&nbsp;</p><p><u>B. Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>Injection-Site and Systemic Adverse Reactions</p><p>Injection-site reactions (pain, swelling, and erythema) and oral temperature were solicited using VRC-aided surveillance for five days after each injection of Gardasil&nbsp; 9 during the clinical studies. The rates and severity of these solicited adverse reactions that occurred within five days following each dose of Gardasil&nbsp; 9 compared with Gardasil&nbsp; in Study 1 (girls and women 16 through 26 years of age) and Study 3 (girls 9 through 15 years of age) are presented in Table 1. Among subjects who received Gardasil&nbsp; 9, the rates of injection-site pain were approximately equal across the three reporting time periods. Rates of injection-site swelling and injection-site erythema increased following each successive dose of Gardasil&nbsp; 9. Recipients of Gardasil&nbsp; 9 had numerically higher rates of injection-site reactions compared with recipients of Gardasil.</p><p><strong>Table 1: Rates (%) and Severity of Solicited Injection-Site and Systemic Adverse Reactions Occurring within Five Days of Each Vaccination with Gardasil&nbsp;9 Compared with Gardasil (Studies 1 and 3)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:654px"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Gardasil&nbsp;9</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Gardasil</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Post-dose 1</strong></p></td><td style="vertical-align:top"><p><strong>Post-dose 2</strong></p></td><td style="vertical-align:top"><p><strong>Post-dose 3</strong></p></td><td style="vertical-align:top"><p><strong>Post any dose </strong></p></td><td style="vertical-align:top"><p><strong>Post-dose 1 </strong></p></td><td style="vertical-align:top"><p><strong>Post-dose 2 </strong></p></td><td style="vertical-align:top"><p><strong>Post-dose 3</strong></p></td><td style="vertical-align:top"><p><strong>Post any dose</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Girls and Women 16 through 26 Years of Age</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Injection-Site Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>N=7069</strong></p></td><td style="vertical-align:top"><p><strong>N=6997</strong></p></td><td style="vertical-align:top"><p><strong>N=6909</strong></p></td><td style="vertical-align:top"><p><strong>N=7071</strong></p></td><td style="vertical-align:top"><p><strong>N=7076</strong></p></td><td style="vertical-align:top"><p><strong>N=6992</strong></p></td><td style="vertical-align:top"><p><strong>N=6909</strong></p></td><td style="vertical-align:top"><p><strong>N=7078</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pain, Any</p></td><td style="vertical-align:top"><p>70.7</p></td><td style="vertical-align:top"><p>73.5</p></td><td style="vertical-align:top"><p>71.6</p></td><td style="vertical-align:top"><p>89.9</p></td><td style="vertical-align:top"><p>58.2</p></td><td style="vertical-align:top"><p>62.2</p></td><td style="vertical-align:top"><p>62.6</p></td><td style="vertical-align:top"><p>83.5</p></td></tr><tr><td style="vertical-align:top"><p>Pain, Severe</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Swelling, Any</p></td><td style="vertical-align:top"><p>12.5</p></td><td style="vertical-align:top"><p>23.3</p></td><td style="vertical-align:top"><p>28.3</p></td><td style="vertical-align:top"><p>40.0</p></td><td style="vertical-align:top"><p>9.3</p></td><td style="vertical-align:top"><p>14.6</p></td><td style="vertical-align:top"><p>18.7</p></td><td style="vertical-align:top"><p>28.8</p></td></tr><tr><td style="vertical-align:top"><p>Swelling, Severe</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>Erythema, Any</p></td><td style="vertical-align:top"><p>10.6</p></td><td style="vertical-align:top"><p>18.0</p></td><td style="vertical-align:top"><p>22.6</p></td><td style="vertical-align:top"><p>34.0</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>12.9</p></td><td style="vertical-align:top"><p>15.6</p></td><td style="vertical-align:top"><p>25.6</p></td></tr><tr><td style="vertical-align:top"><p>Erythema, Severe</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Systemic Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>n=6995</strong></p></td><td style="vertical-align:top"><p><strong>n=6913</strong></p></td><td style="vertical-align:top"><p><strong>n=6743</strong></p></td><td style="vertical-align:top"><p><strong>n=7022</strong></p></td><td style="vertical-align:top"><p><strong>n=7003</strong></p></td><td style="vertical-align:top"><p><strong>n=6914</strong></p></td><td style="vertical-align:top"><p><strong>n=6725</strong></p></td><td style="vertical-align:top"><p><strong>n=7024</strong></p></td></tr><tr><td style="vertical-align:top"><p>Temperature &ge;100&deg;F</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>6.0</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>5.9</p></td></tr><tr><td style="vertical-align:top"><p>Temperature &ge;102&deg;F</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Girls 9 through 15 Years of Age</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Injection-Site Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>N=300</strong></p></td><td style="vertical-align:top"><p><strong>N=297</strong></p></td><td style="vertical-align:top"><p><strong>N=296</strong></p></td><td style="vertical-align:top"><p><strong>N=299</strong></p></td><td style="vertical-align:top"><p><strong>N=299</strong></p></td><td style="vertical-align:top"><p><strong>N=299</strong></p></td><td style="vertical-align:top"><p><strong>N=294</strong></p></td><td style="vertical-align:top"><p><strong>N=300</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pain, Any</p></td><td style="vertical-align:top"><p>71.7</p></td><td style="vertical-align:top"><p>71.0</p></td><td style="vertical-align:top"><p>74.3</p></td><td style="vertical-align:top"><p>89.3</p></td><td style="vertical-align:top"><p>66.2</p></td><td style="vertical-align:top"><p>66.2</p></td><td style="vertical-align:top"><p>69.4</p></td><td style="vertical-align:top"><p>88.3</p></td></tr><tr><td style="vertical-align:top"><p>Pain, Severe</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>2.0</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>3.3</p></td></tr><tr><td style="vertical-align:top"><p>Swelling, Any</p></td><td style="vertical-align:top"><p>14.0</p></td><td style="vertical-align:top"><p>23.9</p></td><td style="vertical-align:top"><p>36.1</p></td><td style="vertical-align:top"><p>47.8</p></td><td style="vertical-align:top"><p>10.4</p></td><td style="vertical-align:top"><p>17.7</p></td><td style="vertical-align:top"><p>25.2</p></td><td style="vertical-align:top"><p>36.0</p></td></tr><tr><td style="vertical-align:top"><p>Swelling, Severe</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>6.0</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>6.3</p></td></tr><tr><td style="vertical-align:top"><p>Erythema, Any</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>15.5</p></td><td style="vertical-align:top"><p>21.3</p></td><td style="vertical-align:top"><p>34.1</p></td><td style="vertical-align:top"><p>9.7</p></td><td style="vertical-align:top"><p>14.4</p></td><td style="vertical-align:top"><p>18.4</p></td><td style="vertical-align:top"><p>29.3</p></td></tr><tr><td style="vertical-align:top"><p>Erythema, Severe</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Systemic Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>n=300</strong></p></td><td style="vertical-align:top"><p><strong>n=294</strong></p></td><td style="vertical-align:top"><p><strong>n=295</strong></p></td><td style="vertical-align:top"><p><strong>n=299</strong></p></td><td style="vertical-align:top"><p><strong>n=299</strong></p></td><td style="vertical-align:top"><p><strong>n=297</strong></p></td><td style="vertical-align:top"><p><strong>n=291</strong></p></td><td style="vertical-align:top"><p><strong>n=300</strong></p></td></tr><tr><td style="vertical-align:top"><p>Temperature &ge;100&deg;F</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3.3</p></td></tr><tr><td style="vertical-align:top"><p>Temperature &ge;102&deg;F</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0.7</p></td></tr></tbody></table><p>The data for girls and women 16 through 26 years of age are from Study 1 (NCT00543543), and the data for girls 9 through 15 years of age are from Study 3 (NCT01304498).</p><p>N=number of subjects vaccinated with safety follow-up</p><p>n=number of subjects with temperature data</p><p>Pain, Any=mild, moderate, severe or unknown intensity</p><p>Pain, Severe=incapacitating with inability to work or do usual activity</p><p>Swelling, Any=any size or size unknown</p><p>Swelling, Severe=maximum size greater than 2 inches</p><p>Erythema, Any=any size or size unknown</p><p>Erythema, Severe=maximum size greater than 2 inches</p><p>&nbsp;</p><p>Unsolicited injection-site and systemic adverse reactions (assessed as vaccine-related by the investigator) observed among recipients of either Gardasil&nbsp;9 or Gardasil in Studies 1 and 3 at a frequency of at least 1% are shown in Table 2. Few individuals discontinued study participation due to adverse experiences after receiving either vaccine (Gardasil&nbsp;9 = 0.1% vs. Gardasil &lt;0.1%).</p><p><strong>Table 2: Rates (%) of Unsolicited Injection-Site and Systemic Adverse Reactions Occurring among &ge;1.0% of Individuals after Any Vaccination with Gardasil&nbsp;9 Compared with Gardasil (Studies 1 and 3)</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Girls and Women 16 through 26 Years of Age</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Girls 9 through 15 Years of Age</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Gardasil&nbsp;9</strong></p><p><strong>N=7071</strong></p></td><td style="vertical-align:top"><p><strong>Gardasil</strong></p><p><strong>N=7078</strong></p></td><td style="vertical-align:top"><p><strong>Gardasil&nbsp;9</strong></p><p><strong>N=299</strong></p></td><td style="vertical-align:top"><p><strong>Gardasil</strong></p><p><strong>N=300</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Injection-Site Adverse Reactions (</strong><strong>1 to 5 Days Post-Vaccination, Any Dose)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>4.0</p></td><td style="vertical-align:top"><p>4.0</p></td><td style="vertical-align:top"><p>2.7</p></td></tr><tr><td style="vertical-align:top"><p>Bruising</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hematoma</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>4.7</p></td></tr><tr><td style="vertical-align:top"><p>Mass</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Induration</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>2.0</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>Warmth</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>1.7</p></td></tr><tr><td style="vertical-align:top"><p>Reaction</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Systemic Adverse Reactions (</strong><strong>1 to 15 Days Post-Vaccination, Any Dose)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>14.6</p></td><td style="vertical-align:top"><p>13.7</p></td><td style="vertical-align:top"><p>11.4</p></td><td style="vertical-align:top"><p>11.3</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>2.7</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>4.4</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2.7</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Oropharyngeal pain</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain, upper</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>1.0</p></td></tr></tbody></table><p>The data for girls and women 16 through 26 years of age are from Study 1 (NCT00543543), and the data for girls 9 through 15 years of age are from Study 3 (NCT01304498).</p><p>N=number of subjects vaccinated with safety follow-up</p><p>&nbsp;</p><p>In an uncontrolled clinical trial with 639 boys and 1,878 girls 9 through 15 years of age (Study 2), the rates and severity of solicited adverse reactions following each dose of Gardasil&nbsp;9 were similar between boys and girls. Rates of solicited and unsolicited injection-site and systemic adverse reactions in boys 9 through 15 years of age were similar to those among girls 9 through 15 years of age. Solicited and unsolicited adverse reactions reported by boys in this study are shown in Table 3.</p><p>In another uncontrolled clinical trial with 1,394 boys and men and 1,075 girls and women 16 through 26 years of age (Study 7), the rates of solicited and unsolicited adverse reactions following each dose of Gardasil&nbsp;9 among girls and women 16 through 26 years of age were similar to those reported in Study 1. Rates of solicited and unsolicited adverse reactions reported by boys and men 16 through 26 years of age in this study are shown in Table 3.</p><p>In an uncontrolled clinical trial with 640 women 27 through 45 years of age and 570 girls and women 16 through 26 years of age (Study 9), the rates of solicited and unsolicited adverse reactions following each dose of Gardasil&nbsp;9 among girls and women 16 through 26 years of age were similar to those reported in Study 1. Rates of solicited and unsolicited adverse reactions reported by women 27 through 45 years of</p><p><strong>&nbsp;</strong></p><p><strong>Table 3: Rates (%) of Solicited and Unsolicited* Injection-Site and Systemic Adverse Reactions among Boys 9 through 15 Years of Age, among Boys and Men 16 through 26 Years of Age and Women 27 through 45 Years of Age Who Received GARDASIL&nbsp;9 (Studies 2, 7, and 9)</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Gardasil&nbsp;9 </strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Boys and Men 16 through 26 Years of Age</strong></p></td><td style="vertical-align:top"><p><strong>N=1394</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Solicited Adverse Reactions (1-5 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Pain, Any</p></td><td style="vertical-align:top"><p>63.4</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Pain, Severe</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Erythema, Any</p></td><td style="vertical-align:top"><p>20.7</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Erythema, Severe</p></td><td style="vertical-align:top"><p>0.4</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Swelling, Any</p></td><td style="vertical-align:top"><p>20.2</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Swelling, Severe</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Oral Temperature &ge;100.0&deg;F<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>4.4</p></td></tr><tr><td style="vertical-align:top"><p>Oral Temperature &ge;102&deg;F</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unsolicited Injection-Site Adverse Reactions (1-5 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Hypersensitivity</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Pruritus</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unsolicited Systemic Adverse Reactions (1-15 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>7.3</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Boys 9 through 15 Years of Age</strong></p></td><td style="vertical-align:top"><p><strong>N=639</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Solicited Adverse Reactions (1-5 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Pain, Any</p></td><td style="vertical-align:top"><p>71.5</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Pain, Severe</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Erythema, Any</p></td><td style="vertical-align:top"><p>24.9</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Erythema, Severe</p></td><td style="vertical-align:top"><p>1.9</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Swelling, Any</p></td><td style="vertical-align:top"><p>26.9</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Swelling, Severe</p></td><td style="vertical-align:top"><p>5.2</p></td></tr><tr><td style="vertical-align:top"><p>Oral Temperature &ge;100.0&deg;F<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>10.4</p></td></tr><tr><td style="vertical-align:top"><p>Oral Temperature &ge;102&deg;F</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unsolicited Injection-Site Adverse Reactions (1-5 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Hematoma</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Induration</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unsolicited Systemic Adverse Reactions (1-15 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>9.4</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>8.9</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Women 27 through 45 Years of Age</strong></p></td><td style="vertical-align:top"><p><strong>N=640</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Solicited Adverse Reactions (1-5 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Pain, Any</p></td><td style="vertical-align:top"><p>82.8</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Pain, Severe</p></td><td style="vertical-align:top"><p>1.9</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Erythema, Any</p></td><td style="vertical-align:top"><p>16.9</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Erythema, Severe</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Swelling, Any</p></td><td style="vertical-align:top"><p>23.3</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Swelling, Severe</p></td><td style="vertical-align:top"><p>1.9</p></td></tr><tr><td style="vertical-align:top"><p>Oral Temperature &ge;100.0&deg;F<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top"><p>Oral Temperature &ge;102&deg;F</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unsolicited Injection-Site Adverse Reactions (1-5 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Pruritus</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Hematoma</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unsolicited Systemic Adverse Reactions (1-15 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>13.6</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>3.4</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>1.7</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>1.7</p></td></tr><tr><td style="vertical-align:top"><p>Oropharyngeal pain</p></td><td style="vertical-align:top"><p>1.1</p></td></tr></tbody></table><p>The data for Gardasil&nbsp;9 boys 9 through 15 years of age are from Study 2 (NCT00943722). The data for boys and men 16 through 26 years of age for Gardasil&nbsp;9 are from Study 7 (NCT01651949). The data for women 27 through 45 years of age are from Study 9 (NCT03158220).</p><p>*Unsolicited adverse reactions reported by &ge;1% of individuals</p><p>N=number of subjects vaccinated with safety follow-up</p><p><sup>&dagger;</sup>For oral temperature: number of subjects with temperature data for boys 9 through 15 years of age N=637; for boys and men 16 through 26 years of age N=1,386; for women 27 through 45 years of age N=640</p><p>Pain, Any=mild, moderate, severe or unknown intensity</p><p>Pain, Severe=incapacitating with inability to work or do usual activity</p><p>Swelling, Any=any size or size unknown</p><p>Swelling, Severe=maximum size greater than 2 inches</p><p>Erythema, Any=any size or size unknown</p><p>Erythema, Severe=maximum size greater than 2 inches</p><p>&nbsp;</p><p>Serious Adverse Events in Clinical Studies</p><p>Serious adverse events were collected throughout the entire study period (range one month to 48 months post-last dose) for the seven clinical studies for Gardasil&nbsp;9. Out of the 15,705 individuals who were administered Gardasil&nbsp;9 and had safety follow-up, 354 reported a serious adverse event; representing 2.3% of the population. As a comparison, of the 7,378 individuals who were administered Gardasil and had safety follow-up, 185 reported a serious adverse event; representing 2.5% of the population. Four Gardasil&nbsp;9 recipients each reported at least one serious adverse event that was determined to be vaccine-related. The vaccine-related serious adverse reactions were pyrexia, allergy to vaccine, asthmatic crisis, and headache.</p><p><em>&nbsp;</em></p><p>Deaths in the Entire Study Population</p><p>Across the clinical studies, ten deaths occurred (five each in the Gardasil&nbsp;9 and Gardasil groups); none were assessed as vaccine-related. Causes of death in the Gardasil&nbsp;9 group included one automobile accident, one suicide, one case of acute lymphocytic leukemia, one case of hypovolemic septic shock, and one unexplained sudden death 678 days following the last dose of Gardasil&nbsp;9. Causes of death in the GARDASIL control group included one automobile accident, one airplane crash, one cerebral hemorrhage, one gunshot wound, and one stomach adenocarcinoma.</p><p><em>&nbsp;</em></p><p>Systemic Autoimmune Disorders</p><p>In all of the clinical trials with Gardasil&nbsp;9 subjects were evaluated for new medical conditions potentially indicative of a systemic autoimmune disorder. In total, 2.2% (351/15,703) of Gardasil&nbsp;9 recipients and 3.3% (240/7,378) of GARDASIL recipients reported new medical conditions potentially indicative of systemic autoimmune disorders, which were similar to rates reported following Gardasil, AAHS control, or saline placebo in historical clinical trials.</p><p>&nbsp;</p><p>Clinical Trials Experience for Gardasil&nbsp;9 in Individuals Who Have Been Previously Vaccinated with GARDASIL</p><p>A clinical study (Study 4) evaluated the safety of Gardasil&nbsp;9 in 12- through 26-year-old girls and women who had previously been vaccinated with three doses of Gardasil. The time interval between the last injection of Gardasil and the first injection of Gardasil&nbsp;9 ranged from approximately 12 to 36 months. Individuals were administered Gardasil&nbsp;9 or saline placebo and safety was evaluated using VRC-aided surveillance for 14 days after each injection of Gardasil&nbsp;9 or saline placebo in these individuals. The individuals who were monitored included 608 individuals who received Gardasil&nbsp;9 and 305 individuals who received saline placebo. Few (0.5%) individuals who received Gardasil&nbsp;9 discontinued due to adverse reactions. The vaccine-related adverse experiences that were observed among recipients of Gardasil&nbsp;9 at a frequency of at least 1.0% and also at a greater frequency than that observed among saline placebo recipients are shown in Table 4. Overall the safety profile was similar between individuals vaccinated with Gardasil&nbsp;9 who were previously vaccinated with Gardasil and those who were na&iuml;ve to HPV vaccination with the exception of numerically higher rates of injection-site swelling and erythema among individuals who were previously vaccinated with Gardasil (Tables 1 and 4).</p><p>&nbsp;</p><p><strong>Table 4: Rates (%) of Solicited and Unsolicited* Injection-Site and Systemic Adverse Reactions among Individuals Previously Vaccinated with Gardasil Who Received Gardasil&nbsp;9 or Saline Placebo (Girls and Women 12 through 26 Years of Age) (Study 4)</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Gardasil&nbsp;9 </strong></p><p><strong>N=608</strong></p></td><td style="vertical-align:top"><p><strong>Saline Placebo</strong></p><p><strong>N=305</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Solicited Adverse Reactions (1-5 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Pain</p></td><td style="vertical-align:top"><p>90.3</p></td><td style="vertical-align:top"><p>38.0</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Erythema</p></td><td style="vertical-align:top"><p>42.3</p></td><td style="vertical-align:top"><p>8.5</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Swelling</p></td><td style="vertical-align:top"><p>49.0</p></td><td style="vertical-align:top"><p>5.9</p></td></tr><tr><td style="vertical-align:top"><p>Oral Temperature &ge;100.0&deg;F<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>3.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unsolicited Injection-Site Adverse Reactions (1-5 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Pruritus</p></td><td style="vertical-align:top"><p>7.7</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Hematoma</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Reaction</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Injection-Site Mass</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unsolicited Systemic Adverse Reactions (1-15 Days Post-Vaccination, Any Dose)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>19.6</p></td><td style="vertical-align:top"><p>18.0</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>5.1</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain, upper</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Influenza</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.0</p></td></tr></tbody></table><p>The data for GARDASIL&nbsp;9 and saline placebo are from Study 4 (NCT01047345).</p><p>*Unsolicited adverse reactions reported by &ge;1% of individuals</p><p>N=number of subjects vaccinated with safety follow-up</p><p><sup>&dagger;</sup>For oral temperature: number of subjects with temperature data Gardasil&nbsp;9 N=604; Saline Placebo N=304</p><p>&nbsp;</p><p>Safety in Concomitant Use with Menactra and Adacel</p><p>In Study 5, the safety of Gardasil&nbsp;9 when administered concomitantly with Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] and Adacel [Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)] was evaluated in a randomized study of 1,241 boys (n = 620) and girls (n = 621) with a mean age of 12.2 years <em>[see Pharmacodynamic Properties (5.1)].</em></p><p>Of the 1,237 boys and girls vaccinated, 1,220 had safety follow-up for injection-site adverse reactions. The rates of injection-site adverse reactions were similar between the concomitant group and non-concomitant group (vaccination with Gardasil&nbsp; 9 separated from vaccination with Menactra and Adacel by 1 month) with the exception of an increased rate of swelling reported at the injection site for Gardasil&nbsp; 9 in the concomitant group (14.4%) compared to the non-concomitant group (9.4%). The majority of injection-site swelling adverse reactions were reported as being mild to moderate in intensity.</p><p>&nbsp;</p><p><strong>Postmarketing Experience</strong></p><p>The postmarketing adverse experiences were reported voluntarily from a population of uncertain size, therefore, it is not possible to reliably estimate their frequency or to establish a causal relationship to vaccine exposure.</p><p>The safety profile of Gardasil&nbsp; 9 and Gardasil&nbsp; are similar. The postmarketing safety experience with Gardasil is relevant to Gardasil&nbsp;9 since the vaccines are manufactured similarly and contain the same L1 HPV proteins of four of the same HPV types.</p><p>&nbsp;</p><p><u>Gardasil&nbsp;9</u></p><p><u>&nbsp;</u></p><p>In addition to the adverse reactions reported in the clinical studies, the following adverse experiences have been spontaneously reported during post-approval use of Gardasil&nbsp;9:</p><p>&nbsp;</p><p>Gastrointestinal disorders: Vomiting</p><p>Skin and subcutaneous tissue disorders: Urticaria</p><p>&nbsp;</p><p><u>Gardasil</u></p><p>&nbsp;</p><p>Additionally, the following postmarketing adverse experiences have been spontaneously reported for Gardasil:</p><p>&nbsp;</p><p>Blood and lymphatic system disorders: Autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, lymphadenopathy.</p><p>Respiratory, thoracic and mediastinal disorders: Pulmonary embolus.</p><p>Gastrointestinal disorders: Pancreatitis.</p><p>General disorders and administration site conditions: Asthenia, chills, death, malaise.</p><p>Immune system disorders: Autoimmune diseases, hypersensitivity reactions including anaphylactic/anaphylactoid reactions, bronchospasm.</p><p>Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.</p><p>Nervous system disorders: Acute disseminated encephalomyelitis, Guillain-Barr&eacute; syndrome, motor neuron disease, paralysis, seizures, transverse myelitis.</p><p>Infections and infestations: Cellulitis.</p><p>Vascular disorders: Deep venous thrombosis.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No cases of overdose have been reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Vaccines, Papillomavirus vaccines, ATC code:<strong> </strong>J07BM03</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest that the efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Efficacy of GARDASIL&nbsp;9 against anogenital diseases related to the vaccine HPV types in human beings is thought to be mediated by humoral immune responses induced by the vaccine, although the exact mechanism of protection is unknown.</p><p>&nbsp;</p><p>NONCLINICAL TOXICOLOGY</p><p><strong>Carcinogenesis, Mutagenesis, Impairment&nbsp;of&nbsp;Fertility</strong></p><p>GARDASIL&nbsp;9 has not been evaluated for the potential to cause carcinogenicity, genotoxicity or impairment of male fertility.</p><p>&nbsp;</p><p>CLINICAL STUDIES</p><p>In these studies, seropositive is defined as anti-HPV titer greater than or equal to the pre-specified serostatus cutoff for a given HPV type. Seronegative is defined as anti-HPV titer less than the pre-specified serostatus cutoff for a given HPV type. The serostatus cutoff is the antibody titer level above the assay&rsquo;s lower limit of quantification that reliably distinguishes sera samples classified by clinical likelihood of HPV infection and positive or negative status by previous versions of competitive Luminex Immunoassay (cLIA). The lower limits of quantification and serostatus cutoffs for each of the 9 vaccine HPV types are shown in Table 5 below. PCR positive is defined as DNA detected for a given HPV type. PCR negative is defined as DNA not detected for a given HPV type. The lower limit of detection for the multiplexed HPV PCR assays ranged from 5 to 34 copies per test across the 9 vaccine HPV types.</p><p>&nbsp;</p><p><strong>Table 5: Competitive Luminex Immunoassay (cLIA) Limits of Quantification and Serostatus Cutoffs for GARDASIL&nbsp;9 HPV Types</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><strong>HPV Type</strong></p></td><td style="vertical-align:bottom"><p><strong>cLIA Lower Limit of Quantification (mMU*/mL)</strong></p></td><td style="vertical-align:bottom"><p><strong>cLIA Serostatus Cutoff</strong></p><p><strong>(mMU*/mL)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>HPV 6</strong></p></td><td style="vertical-align:bottom"><p>16</p></td><td style="vertical-align:bottom"><p>30</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>HPV 11</strong></p></td><td style="vertical-align:bottom"><p>6</p></td><td style="vertical-align:bottom"><p>16</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>HPV 16</strong></p></td><td style="vertical-align:bottom"><p>12</p></td><td style="vertical-align:bottom"><p>20</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>HPV 18</strong></p></td><td style="vertical-align:bottom"><p>8</p></td><td style="vertical-align:bottom"><p>24</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>HPV 31</strong></p></td><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:bottom"><p>10</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>HPV 33</strong></p></td><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:bottom"><p>8</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>HPV 45</strong></p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>8</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>HPV 52</strong></p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>8</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>HPV 58</strong></p></td><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:bottom"><p>8</p></td></tr></tbody></table><p>*mMU=milli-Merck Units</p><p><strong>Efficacy and Effectiveness Data for GARDASIL</strong></p><p>Efficacy and effectiveness of GARDASIL are relevant to GARDASIL&nbsp;9 since the vaccines are manufactured similarly and contain four of the same HPV L1 VLPs.</p><p><em>&nbsp;</em></p><p>Individuals 16 through 26 Years of Age</p><p>Efficacy of GARDASIL was assessed in five AAHS-controlled, double-blind, randomized clinical trials evaluating 24,596 individuals 16 through 26 years of age (20,541 girls and women and 4,055 boys and men). The results of these trials are shown in Table 6 below.</p><p>&nbsp;</p><p><strong>Table 6: Analysis of Efficacy of GARDASIL in the PPE* Population for Vaccine HPV Types</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:655px"><thead><tr><td rowspan="2"><p><strong>Disease Endpoints</strong></p></td><td colspan="2"><p><strong>GARDASIL</strong></p></td><td colspan="2"><p><strong>AAHS Control</strong></p></td><td rowspan="2"><p><strong>% Efficacy (95% CI)</strong></p></td></tr></thead><tbody><tr><td><p><strong>N</strong></p></td><td><p><strong>Number of cases</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>Number of cases</strong></p></td></tr><tr><td colspan="6"><p><strong>16- through 26-Year-Old Girls and Women<sup>&dagger;</sup></strong></p></td></tr><tr><td><p><strong>HPV 16- or 18-related CIN 2/3 or AIS </strong></p></td><td><p>8493</p></td><td><p>2</p></td><td><p>8464</p></td><td><p>112</p></td><td><p>98.2 (93.5, 99.8)</p></td></tr><tr><td><p><strong>HPV 16- or 18-related VIN 2/3 </strong></p></td><td><p>7772</p></td><td><p>0</p></td><td><p>7744</p></td><td><p>10</p></td><td><p>100.0 (55.5, 100.0)</p></td></tr><tr><td><p><strong>HPV 16- or 18-related VaIN 2/3 </strong></p></td><td><p>7772</p></td><td><p>0</p></td><td><p>7744</p></td><td><p>9</p></td><td><p>100.0 (49.5, 100.0)</p></td></tr><tr><td><p><strong>HPV 6-, 11-, 16-, or 18-related CIN (CIN 1, CIN 2/3) or AIS </strong></p></td><td><p>7864</p></td><td><p>9</p></td><td><p>7865</p></td><td><p>225</p></td><td><p>96.0 (92.3, 98.2)</p></td></tr><tr><td><p><strong>HPV 6-, 11-, 16-, or 18-related Genital Warts </strong></p></td><td><p>7900</p></td><td><p>2</p></td><td><p>7902</p></td><td><p>193</p></td><td><p>99.0 (96.2, 99.9)</p></td></tr><tr><td><p><strong>HPV 6- and 11-related Genital Warts </strong></p></td><td><p>6932</p></td><td><p>2</p></td><td><p>6856</p></td><td><p>189</p></td><td><p>99.0 (96.2, 99.9)</p></td></tr><tr><td colspan="6"><p><strong>16- through 26-Year-Old Boys and Men</strong></p></td></tr><tr><td colspan="6"><p><strong>External Genital Lesions HPV 6-, 11-, 16-, or 18-related</strong></p></td></tr><tr><td><p><strong>External Genital Lesions</strong></p></td><td><p>1394</p></td><td><p>3</p></td><td><p>1404</p></td><td><p>32</p></td><td><p>90.6 (70.1, 98.2)</p></td></tr><tr><td><p><strong>Condyloma </strong></p></td><td><p>1394</p></td><td><p>3</p></td><td><p>1404</p></td><td><p>28</p></td><td><p>89.3 (65.3, 97.9)</p></td></tr><tr><td><p><strong>PIN 1/2/3</strong></p></td><td><p>1394</p></td><td><p>0</p></td><td><p>1404</p></td><td><p>4</p></td><td><p>100.0 (-52.1, 100.0)</p></td></tr><tr><td colspan="6"><p><strong>HPV 6-, 11-, 16-, or 18-related Endpoint</strong></p></td></tr><tr><td><p><strong>AIN 1/2/3</strong></p></td><td><p>194</p></td><td><p>5</p></td><td><p>208</p></td><td><p>24</p></td><td><p>77.5 (39.6, 93.3)</p></td></tr><tr><td><p><strong>AIN 2/3</strong></p></td><td><p>194</p></td><td><p>3</p></td><td><p>208</p></td><td><p>13</p></td><td><p>74.9 (8.8, 95.4)</p></td></tr><tr><td><p><strong>AIN 1</strong></p><p><strong>Condyloma Acuminatum<br />Non-acuminate</strong></p></td><td><p>194<br />194<br />194</p></td><td><p>4<br />0<br />4</p></td><td><p>208<br />208<br />208</p></td><td><p>16<br />6<br />11</p></td><td><p>73.0 (16.3, 93.4)<br />100.0 (8.2, 100.0)<br />60.4 (-33.5, 90.8)</p></td></tr></tbody></table><p>*The PPE population consisted of individuals who received all three vaccinations within one year of enrollment, did not have major deviations from the study protocol, were na&iuml;ve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and who remained PCR negative to the relevant HPV type(s) through one month post-dose 3 (Month 7).</p><p><sup>&dagger;</sup>Analyses of the combined trials were prospectively planned and included the use of similar study entry criteria.</p><p>N=Number of individuals with at least one follow-up visit after Month 7</p><p>CI=Confidence Interval</p><p>Note 1: Point estimates and confidence intervals are adjusted for person-time of follow-up.</p><p>Note 2: Table 6 does not include cases due to HPV types not covered by the vaccine.</p><p>AAHS = Amorphous Aluminum Hydroxyphosphate Sulfate, CIN = Cervical Intraepithelial Neoplasia, VIN = Vulvar Intraepithelial Neoplasia, VaIN=Vaginal Intraepithelial Neoplasia, PIN=Penile Intraepithelial Neoplasia, AIN=Anal Intraepithelial Neoplasia, AIS=Adenocarcinoma <em>In Situ</em></p><p>&nbsp;</p><p>In an extension study in females 16 through 26 years of age at enrollment, prophylactic efficacy of GARDASIL through Month 60 against overall cervical and genital disease related to HPV 6, 11, 16, and 18 was 100% (95% CI: 12.3%, 100%) compared to AAHS control.</p><p>An extension study in girls and women 16 through 23 years of age used national health care registries in Denmark, Iceland, Norway, and Sweden to monitor endpoint cases of HPV 6-, 11-, 16-, or 18-related CIN (any grade), AIS, cervical cancer, vulvar cancer, or vaginal cancer among 2,650 girls and women 16 through 23 years of age at enrollment who were randomized to vaccination with GARDASIL. An interim analysis of the per-protocol effectiveness population included 1,902 subjects who completed the GARDASIL vaccination series within one year, were na&iuml;ve to the relevant HPV type through 1 month post-dose 3, had no protocol violations, and had follow-up data available. The median follow-up from the first dose of vaccine was 6.7 years with a range of 2.8 to 8.4 years. At the time of interim analysis, no cases of HPV 6-, 11-, 16-, or 18-related CIN (any grade), AIS, cervical cancer, vulvar cancer, or vaginal cancer were observed over a total of 5,765 person-years at risk.</p><p>&nbsp;</p><p>Girls and Boys 9 through 15 Years of Age</p><p>An extension study of 614 girls and 565 boys 9 through 15 years of age at enrollment who were randomized to vaccination with GARDASIL actively followed subjects for endpoint cases of HPV 6-, 11-, 16-, or 18-related persistent infection, CIN (any grade), AIS, VIN, VaIN, cervical cancer, vulvar cancer, vaginal cancer, and external genital lesions from the initiation of sexual activity or age 16 onwards. An interim analysis of the per-protocol effectiveness population included 246 girls and 168 boys who completed the GARDASIL vaccination series within one year, were seronegative to the relevant HPV type at initiation of the vaccination series, and had not initiated sexual activity prior to receiving the third dose of GARDASIL. The median follow-up from the first dose of vaccine was 7.2 years with a range of 0.5 to 8.5 years. At the time of interim analysis, no cases of persistent infection of at least 12 months&rsquo; duration and no cases of HPV 6-, 11-, 16-, or 18-related CIN (any grade), AIS, VIN, VaIN, cervical cancer, vulvar cancer, vaginal cancer, or external genital lesions were observed over a total 1,105 person-years at risk. There were 4 cases of HPV 6-, 11-, 16-, or 18-related persistent infection of at least 6 months&rsquo; duration, including 3 cases related to HPV 16 and 1 case related to HPV 6, none of which persisted to 12 months&rsquo; duration.</p><p>&nbsp;</p><p>Individuals 27 through 45 Years of Age</p><p>A clinical trial evaluated efficacy of GARDASIL in 3,253 women 27 through 45 years of age, based on a combined endpoint of HPV 6-, 11-, 16- or 18-related persistent infection, genital warts, vulvar and vaginal dysplastic lesions of any grade, CIN of any grade, AIS, and cervical cancer. These women were randomized 1:1 to receive either GARDASIL or AAHS control. The clinical trial was conducted in two phases: a base study and a long-term study extension. The per-protocol efficacy (PPE) population received all three vaccinations within one year of enrollment, did not have major deviations from the study protocol, were na&iuml;ve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16 and 18) prior to dose 1 and remained PCR negative to the relevant HPV type(s) through one month post-dose 3 (Month 7).</p><p>In the base study (median duration of follow-up of 3.5 years post-dose 3), the efficacy of GARDASIL against the combined incidence of HPV 6-, 11-, 16-, and 18-related persistent infection, genital warts, VIN, VaIN, vulvar cancer, vaginal cancer, cervical dysplasia (any grade CIN), AIS and cervical cancer in the PPE population was 87.7% (95% CI: 75.4%, 94.6%). The efficacy estimate for the combined endpoint was driven primarily by prevention of persistent infection. The efficacy of GARDASIL against the combined incidence of HPV 6-, 11-, 16-, and 18-related genital warts or cervical dysplasia was 95.0% (95% CI: 68.7%, 99.9%) in the PPE population. While no statistically significant efficacy was demonstrated for GARDASIL in the base study for prevention of cervical intraepithelial neoplasia grades 2 and 3 (CIN 2/3), adenocarcinoma <em>in situ</em> (AIS) or cervical cancer related to HPV types 16 and 18, there was 1 case of CIN 2/3 observed in the GARDASIL group and 5 cases in the placebo group. The CIN 2 case in the GARDASIL group tested positive by PCR for HPV 16 and HPV 51.</p><p>In the long-term extension of this study, subjects from Colombia (n=600) randomized to the GARDASIL group in the base study were monitored for HPV 6-, 11-, 16-, and 18-related genital warts or cervical dysplasia. The median follow-up post-dose 3 was 8.9 years with a range of 0.1 to 10.1 years over a total of 3,518 person-years. During the long-term extension phase, no cases of HPV 6-, 11-, 16-, or 18-related CIN (any grade) or genital warts were observed in the PPE population.</p><p>Effectiveness of GARDASIL in men 27 through 45 years of age is inferred from efficacy data in women 27 through 45 years of age as described above and supported by immunogenicity data from a clinical trial in which 150 men, 27 through 45 years of age, received a 3-dose regimen of GARDASIL (0, 2, 6 months). A cross-study analysis of per-protocol immunogenicity populations compared Month 7 anti-HPV 6, 11, 16, and 18 GMTs of these 27- through 45-year-old men (Study A) to those of 16- through 26-year old boys and men (Study B) in whom efficacy of GARDASIL had been established (see Table 6). GMT ratios (Study A/Study B) for HPV 6, 11, 16, and 18 were 0.82 (95%CI: 0.65, 1.03), 0.79 (95%CI: 0.66, 0.93), 0.91 (95%CI: 0.72, 1.13), and 0.74 (95%CI: 0.59, 0.92), respectively.</p><p><strong>Clinical Trials for GARDASIL&nbsp;9</strong></p><p>&nbsp;</p><p>Efficacy and/or immunogenicity of the 3-dose regimen of GARDASIL&nbsp;9 were assessed in seven clinical trials. Study 1 evaluated the efficacy of GARDASIL&nbsp;9 to prevent HPV-related cervical, vulvar, and vaginal disease using GARDASIL as a comparator.</p><p>The analysis of efficacy for GARDASIL&nbsp;9 was evaluated in the per-protocol efficacy (PPE) population of 16- through 26-year-old girls and women, who received all three vaccinations within one year of enrollment, did not have major deviations from the study protocol, and were na&iuml;ve to the relevant HPV type(s) by serology and PCR of cervicovaginal specimens prior to dose one and who remained PCR negative for the relevant HPV type(s) through one month post-dose 3 (Month 7). Overall, approximately 52% of subjects were negative to all vaccine HPV types by both PCR and serology at Day 1.</p><p>The primary analysis of efficacy against HPV Types 31, 33, 45, 52, and 58 is based on a combined endpoint of Cervical Intraepithelial Neoplasia (CIN) 2, CIN 3, Adenocarcinoma <em>in situ</em> (AIS), invasive cervical carcinoma, Vulvar Intraepithelial Neoplasia (VIN) 2/3, Vaginal Intraepithelial Neoplasia (VaIN) 2/3, vulvar cancer, or vaginal cancer. Other endpoints evaluated include cervical, vulvar and vaginal disease of any grade, persistent infection, cytological abnormalities and invasive procedures. For all endpoints, the efficacy against the HPV Types 31, 33, 45, 52 and 58 in GARDASIL&nbsp;9 was evaluated compared with GARDASIL. Efficacy of GARDASIL&nbsp;9 against anal lesions caused by HPV Types 31, 33, 45, 52, and 58 was not assessed due to low incidence. Effectiveness of GARDASIL&nbsp;9 against anal lesions was inferred from the efficacy of GARDASIL against anal lesions caused by HPV types 6, 11, 16 and 18 in men and antibody responses elicited by GARDASIL&nbsp;9 against the HPV types covered by the vaccine.</p><p>Effectiveness against disease caused by HPV Types 6, 11, 16, and 18 was assessed by comparison of geometric mean titers (GMTs) of type-specific antibodies following vaccination with GARDASIL&nbsp;9 with those following vaccination with GARDASIL (Study 1 and Study 3). The effectiveness of GARDASIL&nbsp;9 in girls and boys 9 through 15 years old and in boys and men 16 through 26 years old was inferred based on a comparison of type-specific antibody GMTs to those of 16 through 26-year-old girls and women following vaccination with GARDASIL&nbsp;9. Immunogenicity analyses were performed in the per-protocol immunogenicity (PPI) population consisting of individuals who received all three vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met pre-defined day range for serum collection for assessment of antibody response and were na&iuml;ve [PCR negative (in girls and women 16 through 26 years of age; Studies 1 and 2) and seronegative (Studies 1, 2, 3, 5, 7 and 8)] to the relevant HPV type(s) prior to dose 1 and among 16- through 26-year-old girls and women (Studies 1 and 2) remained PCR negative to the relevant HPV type(s) through Month 7. Pre-defined day ranges for vaccinations were relative to Day 1 (dose 1). For the 3-dose schedule, dose 2 was at 2 months (&plusmn; 3 weeks) and dose 3 was at 6 months (&plusmn; 4 weeks). For the 2-dose schedule, dose 2 was at 6 or 12 months (&plusmn; 4 weeks). Pre-defined day range for serum collection for assessment of antibody response was 21 to 49 days after the last dose.</p><p>Study 1 evaluated immunogenicity of GARDASIL&nbsp;9 and efficacy to prevent infection and disease caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in 16- through 26-year-old girls and women. Study 2 evaluated immunogenicity of GARDASIL&nbsp;9 in girls and boys 9 through 15 years of age and women 16 through 26 years of age. Study 3 evaluated immunogenicity of GARDASIL&nbsp;9 compared with GARDASIL in girls 9 through 15 years of age. Study 4 evaluated administration of GARDASIL&nbsp;9 to girls and women 12 through 26 years of age previously vaccinated with GARDASIL. Study 5 evaluated GARDASIL&nbsp;9 concomitantly administered with Menactra and Adacel in girls and boys 11 through 15 years of age. Together, these five clinical trials evaluated 12,233 individuals who received GARDASIL&nbsp;9 (8,048 girls and women 16 through 26 years of age at enrollment with a mean age of 21.8 years; 2,927 girls 9 through 15 years of age at enrollment with a mean age of 11.9 years; and 1,258 boys 9 through 15 years of age at enrollment with a mean age of 11.9 years. Study 7 evaluated immunogenicity of GARDASIL&nbsp;9 in boys and men, including 1,106 self-identified as heterosexual men (HM) and 313 self-identified as men having sex with men (MSM), 16 through 26 years of age at enrollment (mean ages 20.8 years and 22.2 years, respectively) and 1,101 girls and women 16 through 26 years of age at enrollment (mean age 21.3 years). Study 9 evaluated immunogenicity of GARDASIL&nbsp;9 in 640 women 27 through 45 years of age and 570 girls and women 16 through 26 years of age (mean ages 35.8 years and 21.6 years, respectively).</p><p>The race distribution of the 16- through 26-year-old girls and women in the clinical trials was as follows: 56.8% White; 25.2% Other; 14.1% Asian; and 3.9% Black. The race distribution of the 9- through 15-year-old girls in the clinical trials was as follows: 60.3% White; 19.3% Other; 13.5% Asian; and 7.0% Black. The race distribution of the 9- through 15-year-old boys in the clinical trials was as follows: 46.6% White; 34.3% Other; 13.3% Asian; and 5.9% Black. The race distribution of the 16- through 26-year-old boys and men in the clinical trials was as follows: 62.1% White; 22.6% Other; 9.8% Asian; and 5.5% Black.</p><p>In Study 9 the race distribution of 27- through 45-year-old women was as follows: 97.7% White, 1.6% Asian, 0.3% Other or Multiracial, and 0.5% Black. The race distribution of girls and women 16 through 26 years of age in this study was as follows: 94.6% White, 3.0% Asian, 1.6% Other or Multiracial, and 0.9% Black.</p><p>One clinical trial (Study 8) assessed the 2-dose regimen of GARDASIL&nbsp;9. Study 8 evaluated the immunogenicity of 2 doses of GARDASIL&nbsp;9 in girls and boys 9 through 14 years of age and 3 doses of GARDASIL&nbsp;9 in girls 9 through 14 years of age and women 16 through 26 years of age; (N=1,518; 753 girls; 451 boys and 314 women). The mean age for the girls and boys 9 through 14 years of age was 11.5 years; the mean age for girls and women 16 through 26 years of age was 21.0 years. In Study 8, the race distribution was as follows: 61.1% White; 16.3% Asian; 13.3% Other; and 8.9% Black.</p><p><strong>Efficacy &ndash; HPV Types 31, 33, 45, 52 and 58 in Girls and Women 16 through 26 Years of Age</strong></p><p>Studies Supporting the Efficacy of GARDASIL&nbsp;9 against HPV Types 31, 33, 45, 52, and 58</p><p>The efficacy of GARDASIL&nbsp;9 in 16- through 26-year-old girls and women was assessed in an active comparator-controlled, double-blind, randomized clinical trial (Study 1) that included a total of 14,204 women (GARDASIL&nbsp;9 = 7,099; GARDASIL = 7,105) who were enrolled and vaccinated without pre-screening for the presence of HPV infection. Subjects were followed up with a median duration of 40 months (range 0 to 64 months) after the last vaccination.</p><p>The primary efficacy evaluation was conducted in the PPE population based on a composite clinical endpoint of HPV 31-, 33-, 45-, 52-, and 58-related cervical cancer, vulvar cancer, vaginal cancer, CIN 2/3 or AIS, VIN 2/3, and VaIN 2/3. Efficacy was further evaluated with the clinical endpoints of HPV 31-, 33-, 45-, 52-, and 58-related CIN 1, vulvar and vaginal disease of any grade, and persistent infection. In addition, the study also evaluated the impact of GARDASIL&nbsp;9 on the rates of HPV 31-, 33-, 45-, 52-, and 58-related abnormal Papanicolaou (Pap) tests, cervical and external genital biopsy, and definitive therapy [including loop electrosurgical excision procedure (LEEP) and conization]. Efficacy for all endpoints was measured starting after the Month 7 visit.</p><p>GARDASIL&nbsp;9 prevented HPV 31-, 33-, 45-, 52-, and 58-related persistent infection and disease and also reduced the incidence of HPV 31-, 33-, 45-, 52-, and 58-related Pap test abnormalities, cervical and external genital biopsy, and definitive therapy (Table 7).</p><p>&nbsp;</p><p><strong>Table 7: Analysis of Efficacy of GARDASIL&nbsp;9 against HPV Types 31, 33, 45, 52, and 58 in the PPE* Population of 16-&nbsp;through 26-Year-old Girls and Women (Study 1)</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td rowspan="2"><p><strong>Disease Endpoint</strong></p></td><td colspan="2"><p><strong>GARDASIL&nbsp;9<br />N<sup>&dagger;</sup>=7099</strong></p></td><td colspan="2"><p><strong>GARDASIL<br />N<sup>&dagger;</sup>=7105</strong></p></td><td rowspan="2"><p><strong>GARDASIL&nbsp;9 Efficacy</strong></p><p><strong>%</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td><p><strong>n</strong><strong><sup>&Dagger;</sup></strong></p></td><td><p>&nbsp;<strong>Number of cases</strong></p></td><td><p><strong>n</strong><strong><sup>&Dagger;</sup></strong></p></td><td><p><strong>Number of cases</strong></p></td></tr></thead><tbody><tr><td><p><strong>HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3, AIS, Cervical Cancer, VIN 2/3, VaIN 2/3, Vulvar Cancer, and Vaginal Cancer </strong></p></td><td><p>6016</p></td><td><p>1</p></td><td><p>6017</p></td><td><p>30</p></td><td><p>96.7</p><p>(80.9, 99.8)</p></td></tr><tr><td><p><strong>HPV 31-, 33-, 45-, 52-, 58-related CIN 1</strong></p></td><td><p>5948</p></td><td><p>1</p></td><td><p>5943</p></td><td><p>69</p></td><td><p>98.6</p><p>(92.4, 99.9)</p></td></tr><tr><td><p><strong>HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3 or AIS</strong></p></td><td><p>5948</p></td><td><p>1</p></td><td><p>5943</p></td><td><p>27</p></td><td><p>96.3</p><p>(79.5, 99.8)</p></td></tr><tr><td><p><strong>HPV 31-, 33-, 45-, 52-, 58-related Vulvar or Vaginal Disease</strong></p></td><td><p>6009</p></td><td><p>1</p></td><td><p>6012</p></td><td><p>16</p></td><td><p>93.8</p><p>(61.5, 99.7)</p></td></tr><tr><td><p><strong>HPV 31-, 33-, 45-, 52-, 58-related Persistent Infection &ge;6 Months<sup>&sect;</sup></strong></p></td><td><p>5939</p></td><td><p>26</p></td><td><p>5953</p></td><td><p>642</p></td><td><p>96.2</p><p>(94.4, 97.5)</p></td></tr><tr><td><p><strong>HPV 31-, 33-, 45-, 52-, 58-related Persistent Infection &ge;12 Months<sup>&para;</sup></strong></p></td><td><p>5939</p></td><td><p>15</p></td><td><p>5953</p></td><td><p>375</p></td><td><p>96.1</p><p>(93.7, 97.9)</p></td></tr><tr><td><p><strong>HPV 31-, 33-, 45-, 52-, 58-related ASC-US HR-HPV Positive or Worse Pap<sup>#</sup> Abnormality</strong></p></td><td><p>5881</p></td><td><p>35</p></td><td><p>5882</p></td><td><p>462</p></td><td><p>92.6</p><p>(89.7, 94.8)</p></td></tr><tr><td><p><strong>HPV 31-, 33-, 45-, 52-, 58-related Biopsy</strong></p></td><td><p>6016</p></td><td><p>7</p></td><td><p>6017</p></td><td><p>222</p></td><td><p>96.9</p><p>(93.6, 98.6)</p></td></tr><tr><td><p><strong>HPV 31-, 33-, 45-, 52-, 58-related Definitive Therapy<sup>&THORN;</sup></strong></p></td><td><p>6012</p></td><td><p>4</p></td><td><p>6014</p></td><td><p>32</p></td><td><p>87.5</p><p>(65.7, 96.0)</p></td></tr></tbody></table><p>*The PPE population consisted of individuals who received all three vaccinations within one year of enrollment, did not have major deviations from the study protocol, were na&iuml;ve (PCR negative and seronegative) to the relevant HPV type(s) (Types 31, 33, 45, 52, and 58) prior to dose 1, and who remained PCR negative to the relevant HPV type(s) through one month post-dose 3 (Month 7); data from Study 1 (NCT00543543).</p><p><sup>&dagger;</sup>N=Number of individuals randomized to the respective vaccination group who received at least one injection</p><p><sup>&Dagger;</sup>n=Number of individuals contributing to the analysis</p><p><sup>&sect;</sup>Persistent infection detected in samples from two or more consecutive visits at least six months apart</p><p><sup>&para;</sup>Persistent infection detected in samples from two or more consecutive visits over 12 months or longer</p><p><sup>#</sup>Papanicolaou test</p><p><sup>&THORN;</sup>Including loop electrosurgical excision procedure (LEEP) and conization</p><p>CI=Confidence Interval</p><p>CIN=Cervical Intraepithelial Neoplasia, VIN=Vulvar Intraepithelial Neoplasia, VaIN=Vaginal Intraepithelial Neoplasia, AIS=Adenocarcinoma <em>In Situ</em>, ASC-US=Atypical squamous cells of undetermined significance</p><p>HR=High Risk</p><p>&nbsp;</p><p><strong>Long term Follow-up of Individuals Vaccinated with GARDASIL&nbsp;9</strong></p><p>In an extension study of individuals in Study 2, 971 girls and 301 boys 9 through 15 years of age at enrollment who received a 3-dose regimen of GARDASIL&nbsp;9 were actively followed from age 16 onwards for endpoint cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related persistent infection and disease. For girls, disease endpoints assessed included HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related CIN (any grade), AIS, VIN, VaIN, external genital warts, cervical cancer, vulvar cancer and vaginal cancer. For boys, the disease endpoints assessed included HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related PIN, external genital warts, penile cancer, perineal cancer and perianal cancer.</p><p>Analysis of the per-protocol population included 872 girls and 262 boys who completed the GARDASIL&nbsp;9 vaccination series within one year, were seronegative to the relevant HPV type at initiation of the vaccination series and had not initiated sexual activity prior to receiving the third dose of GARDASIL&nbsp;9. The median follow-up from the last dose of vaccine was 10.0 years with a range of 3.0 to 11.0 years in girls 9 through 15 years of age and 9.9 years with a range of 3.0 to 10.6 years in boys 9 through 15 years of age.</p><p>In girls, no cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related CIN 2/3, AIS, VIN, VaIN, external genital warts, cervical cancer, vulvar cancer or vaginal cancer were observed over a total of 4,576.1 person-years at risk. One case of CIN1 that tested positive for HPV 16, 39 and 59 by PCR was observed. In boys, no cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related PIN, external genital warts, penile cancer, perineal cancer or perianal cancer were observed over a total of 1,278.6 person-years at risk.</p><p>Incidence rates of vaccine HPV types-related persistent infections of at least 6 months duration in girls and boys observed during the study were 52.4 (95% CI: 33.6, 78.0) and 54.6 (95% CI: 21.9, 112.4) cases per 10,000&nbsp;person-years, respectively, and within the range of incidence rates reported in vaccinated cohorts of similar age based on results from previous efficacy studies of GARDASIL&nbsp;9, (which were 36.6 and 21.5 per 10,000 person years for HPV 6-, 11-, 16- and 18-related and HPV 31-, 33-, 45-, 52-, and 58-related persistent infections, respectively, in females in Study 1) and GARDASIL (which were 30 and 59 per 10,000 person-years, for HPV 6-, 11-, 16- and 18-related persistent infections in GARDASIL studies in females and males, respectively).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Effectiveness in Prevention of HPV-Related Oropharyngeal and Other Head and Neck Cancers</strong></p><p>The effectiveness of GARDASIL&nbsp;9 against oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, is based on the effectiveness of GARDASIL and GARDASIL&nbsp;9 to prevent anogenital disease caused by HPV types covered by the vaccine <em>[Pharmacodynamic Properties (5.1,)].</em></p><p><em>&nbsp;</em></p><p><strong>Immunogenicity of a 3-Dose Regimen</strong></p><p>The minimum anti-HPV titer that confers protective efficacy has not been determined.</p><p>Type-specific immunoassays (i.e., cLIA) with type-specific standards were used to assess immunogenicity to each vaccine HPV type. These assays measured antibodies against neutralizing epitopes for each HPV type. The scales for these assays are unique to each HPV type; thus, comparisons across types and to other assays are not appropriate. Immunogenicity was measured by (1) the percentage of individuals who were seropositive for antibodies against the relevant vaccine HPV type, and (2) the Geometric Mean Titer (GMT).</p><p>&nbsp;</p><p>Studies Supporting the Effectiveness of GARDASIL&nbsp;9 against HPV Types 6, 11, 16, and 18</p><p>Effectiveness of GARDASIL&nbsp;9 against persistent infection and disease related to HPV Types 6, 11, 16, or 18 was inferred from non-inferiority comparisons in Study 1 (16- through 26-year-old girls and women) and Study 3 (9- through 15-year-old girls) of GMTs following vaccination with GARDASIL&nbsp;9 with those following vaccination with GARDASIL. A low number of efficacy endpoint cases related to HPV types 6, 11, 16 and 18 in both vaccination groups precluded a meaningful assessment of efficacy using disease endpoints associated with these HPV types. The primary analyses were conducted in the per-protocol population, which included subjects who received all three vaccinations within one year of enrollment, did not have major deviations from the study protocol, and were HPV-na&iuml;ve. HPV-na&iuml;ve individuals were defined as seronegative to the relevant HPV type(s) prior to dose 1 and among female subjects 16 through 26 years of age in Study 1 PCR negative to the relevant HPV type(s) in cervicovaginal specimens prior to dose 1 through Month 7.</p><p>Anti-HPV 6, 11, 16 and 18 GMTs at Month 7 for GARDASIL&nbsp;9 among girls 9 through 15 years of age and young women 16 through 26 years of age were non-inferior to those among the corresponding populations for GARDASIL (Table 8). At least 99.7% of individuals included in the analyses for each HPV type became seropositive by Month 7.</p><p>&nbsp;</p><p><strong>Table 8: Comparison of Immune Responses (Based on cLIA) Between GARDASIL&nbsp;9 and GARDASIL for HPV Types 6, 11, 16, and 18 in the PPI* Population of 9- through 26-Year-Old Girls and Women (Studies 1 and 3)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:631px"><thead><tr><td rowspan="2"><p><strong>Population</strong></p></td><td colspan="2"><p><strong>GARDASIL&nbsp;9</strong></p></td><td colspan="2"><p><strong>GARDASIL</strong></p></td><td colspan="2"><p><strong>GARDASIL&nbsp;9/<br />GARDASIL</strong></p></td></tr><tr><td><p><strong>N<sup>&dagger;</sup></strong></p><p><strong>(n<sup>&Dagger;</sup>)</strong></p></td><td><p><strong>GMT<br />mMU<sup>&sect;/</sup>mL</strong></p></td><td><p><strong>N<sup>&dagger;</sup></strong></p><p><strong>(n<sup>&Dagger;</sup>)</strong></p></td><td><p><strong>GMT<br />mMU<sup>&sect;/</sup>mL</strong></p></td><td><p><strong>GMT<br />Ratio</strong></p></td><td><p><strong>(95% CI)<sup>&para;</sup></strong></p></td></tr></thead><tbody><tr><td colspan="7"><p><strong>Anti-HPV 6</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>300</p><p>(273)</p></td><td><p>1679.4</p></td><td><p>300</p><p>(261)</p></td><td><p>1565.9</p></td><td><p>1.07</p></td><td><p>(0.93, 1.23)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>6792</p><p>(3993)</p></td><td><p>893.1</p></td><td><p>6795</p><p>(3975)</p></td><td><p>875.2</p></td><td><p>1.02</p></td><td><p>(0.99, 1.06)</p></td></tr><tr><td colspan="7"><p><strong>Anti-HPV 11</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>300</p><p>(273)</p></td><td><p>1315.6</p></td><td><p>300</p><p>(261)</p></td><td><p>1417.3</p></td><td><p>0.93</p></td><td><p>(0.80, 1.08)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>6792</p><p>(3995)</p></td><td><p>666.3</p></td><td><p>6795</p><p>(3982)</p></td><td><p>830.0</p></td><td><p>0.80</p></td><td><p>(0.77, 0.83)</p></td></tr><tr><td colspan="7"><p><strong>Anti-HPV 16</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>300</p><p>(276)</p></td><td><p>6739.5</p></td><td><p>300</p><p>(270)</p></td><td><p>6887.4</p></td><td><p>0.97</p></td><td><p>(0.85, 1.11)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>6792</p><p>(4032)</p></td><td><p>3131.1</p></td><td><p>6795</p><p>(4062)</p></td><td><p>3156.6</p></td><td><p>0.99</p></td><td><p>(0.96, 1.03)</p></td></tr><tr><td colspan="7"><p><strong>Anti-HPV 18</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>300</p><p>(276)</p></td><td><p>1956.6</p></td><td><p>300</p><p>(269)</p></td><td><p>1795.6</p></td><td><p>1.08</p></td><td><p>(0.91, 1.29)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>6792</p><p>(4539)</p></td><td><p>804.6</p></td><td><p>6795</p><p>(4541)</p></td><td><p>678.7</p></td><td><p>1.19</p></td><td><p>(1.14, 1.23)</p></td></tr></tbody></table><p>*The PPI population consisted of individuals who received all three vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, were na&iuml;ve (PCR negative [among 16- through 26-year old girls and women] and seronegative) to the relevant HPV type(s) (types 6, 11, 16, and 18) prior to dose 1, and among 16- through 26-year-old girls and women remained PCR negative to the relevant HPV type(s) through one month post-dose 3 (Month 7). The data for 16- through 26-year-old girls and women are from Study 1 (NCT00543543), and the data for 9- through 15-year-old girls are from Study 3 (NCT01304498).</p><p><sup>&dagger;</sup>N=Number of individuals randomized to the respective vaccination group who received at least one injection</p><p><sup>&Dagger;</sup>n=Number of individuals contributing to the analysis</p><p><sup>&sect;</sup>mMU=milli-Merck Units</p><p><sup>&para;</sup>Demonstration of non-inferiority required that the lower bound of the 95% CI of the GMT ratio be greater than 0.67</p><p>CI=Confidence Interval</p><p>GMT=Geometric Mean Titer</p><p>cLIA=competitive Luminex Immunoassay</p><p>&nbsp;</p><p>Study Supporting the Effectiveness of GARDASIL&nbsp;9 against Vaccine HPV Types in 9- through 15-Year-Old Girls and Boys</p><p>Effectiveness of GARDASIL&nbsp;9 against persistent infection and disease related to vaccine HPV types in 9- through 15-year-old girls and boys was inferred from non-inferiority comparison conducted in the PPI population in Study 2 of GMTs following vaccination with GARDASIL&nbsp;9 among 9- through 15-year-old girls and boys with those among 16- through 26-year-old girls and women. Anti-HPV GMTs at Month 7 among 9- through 15-year-old girls and boys were non-inferior to anti-HPV GMTs among 16- through 26-year-old girls and women (Table 9).</p><p>&nbsp;</p><p><strong>Table 9: Comparison of Immune Responses (Based on cLIA) between the PPI* Populations of 16- through 26-Year-Old Girls and Women, 9- through 15-Year-Old Girls, and 9- through 15-Year-Old Boys for All GARDASIL&nbsp;9 Vaccine HPV Types (Study 2)</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:631px"><thead><tr><td><p><strong>Population</strong></p></td><td><p><strong>N<sup>&dagger;</sup></strong></p></td><td><p><strong>n<sup>&Dagger;</sup></strong></p></td><td><p><strong>GMT<br />mMU<sup>&sect;</sup>/mL</strong></p></td><td style="vertical-align:top"><p><strong>GMT Ratio relative to 16- through 26-year-old girls and women<br />(95% CI)<sup>&para;</sup></strong></p></td></tr></thead><tbody><tr><td colspan="5"><p><strong>Anti-HPV 6</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>630</p></td><td><p>503</p></td><td><p>1703.1</p></td><td><p>1.89 (1.68, 2.12)</p></td></tr><tr><td><p>9- through 15-year-old boys</p></td><td><p>641</p></td><td><p>537</p></td><td><p>2083.4</p></td><td><p>2.31 (2.06, 2.60)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>463</p></td><td><p>328</p></td><td><p>900.8</p></td><td><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 11</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>630</p></td><td><p>503</p></td><td><p>1291.5</p></td><td><p>1.83 (1.63, 2.05)</p></td></tr><tr><td><p>9- through 15-year-old boys</p></td><td><p>641</p></td><td><p>537</p></td><td><p>1486.3</p></td><td><p>2.10 (1.88, 2.36)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>463</p></td><td><p>332</p></td><td><p>706.6</p></td><td><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 16</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>630</p></td><td><p>513</p></td><td><p>6933.9</p></td><td><p>1.97 (1.75, 2.21)</p></td></tr><tr><td><p>9- through 15-year-old boys</p></td><td><p>641</p></td><td><p>546</p></td><td><p>8683.0</p></td><td><p>2.46 (2.20, 2.76)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>463</p></td><td><p>329</p></td><td><p>3522.6</p></td><td><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 18</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>630</p></td><td><p>516</p></td><td><p>2148.3</p></td><td><p>2.43 (2.12, 2.79)</p></td></tr><tr><td><p>9- through 15-year-old boys</p></td><td><p>641</p></td><td><p>544</p></td><td><p>2855.4</p></td><td><p>3.23 (2.83, 3.70)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>463</p></td><td><p>345</p></td><td><p>882.7</p></td><td><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 31</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>630</p></td><td><p>506</p></td><td><p>1894.7</p></td><td><p>2.51 (2.21, 2.86)</p></td></tr><tr><td><p>9- through 15-year-old boys</p></td><td><p>641</p></td><td><p>543</p></td><td><p>2255.3</p></td><td><p>2.99 (2.63, 3.40)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>463</p></td><td><p>340</p></td><td><p>753.9</p></td><td><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 33</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>630</p></td><td><p>518</p></td><td><p>985.8</p></td><td><p>2.11 (1.88, 2.37)</p></td></tr><tr><td><p>9- through 15-year-old boys</p></td><td><p>641</p></td><td><p>544</p></td><td><p>1207.4</p></td><td><p>2.59 (2.31, 2.90)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>463</p></td><td><p>354</p></td><td><p>466.8</p></td><td><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 45</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>630</p></td><td><p>518</p></td><td><p>707.7</p></td><td><p>2.60 (2.25, 3.00)</p></td></tr><tr><td><p>9- through 15-year-old boys</p></td><td><p>641</p></td><td><p>547</p></td><td><p>912.1</p></td><td><p>3.35 (2.90, 3.87)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>463</p></td><td><p>368</p></td><td><p>272.2</p></td><td><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 52</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>630</p></td><td><p>517</p></td><td><p>962.2</p></td><td><p>2.21 (1.96, 2.49)</p></td></tr><tr><td><p>9- through 15-year-old boys</p></td><td><p>641</p></td><td><p>545</p></td><td><p>1055.5</p></td><td><p>2.52 (2.22, 2.84)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>463</p></td><td><p>337</p></td><td><p>419.6</p></td><td><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 58</strong></p></td></tr><tr><td><p>9- through 15-year-old girls</p></td><td><p>630</p></td><td><p>516</p></td><td><p>1288.0</p></td><td><p>2.18 (1.94, 2.46)</p></td></tr><tr><td><p>9- through 15-year-old boys</p></td><td><p>641</p></td><td><p>544</p></td><td><p>1593.3</p></td><td><p>2.70 (2.40, 3.03)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>463</p></td><td><p>332</p></td><td><p>590.5</p></td><td><p>1</p></td></tr></tbody></table><p>*The PPI population consisted of individuals who received all three vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, were na&iuml;ve (PCR negative [among 16- through 26-year old girls and women] and seronegative) to the relevant HPV type(s) prior to dose 1 and among 16- through 26-year-old girls and women remained PCR negative to the relevant HPV types through one month post-dose 3 (Month 7). The data are from Study 2 (NCT00943722).</p><p><sup>&dagger;</sup>N=Number of individuals randomized to the respective vaccination group who received at least one injection</p><p><sup>&Dagger;</sup>n=Number of individuals contributing to the analysis</p><p><sup>&sect;</sup>mMU=milli-Merck Units</p><p><sup>&para;</sup>Demonstration of non-inferiority required that the lower bound of the 95% CI of the GMT ratio be greater than 0.67</p><p>cLIA=competitive Luminex Immunoassay</p><p>CI=Confidence Interval</p><p>GMT=Geometric Mean Titer</p><p>&nbsp;</p><p>Study Supporting the Effectiveness of GARDASIL&nbsp;9 against Vaccine HPV Types in 16- through 26-Year-Old Boys and Men</p><p>Effectiveness of GARDASIL&nbsp;9 against persistent infection and disease related to vaccine HPV types in 16- through 26-year-old boys and men was inferred from non-inferiority comparison conducted in the PPI population in Study 7 of GMTs following vaccination with GARDASIL&nbsp;9 among 16- through 26-year-old HM with those among 16- through 26-year-old girls and women. Anti-HPV GMTs at Month 7 among 16- through 26-year-old HM were non-inferior to anti-HPV GMTs among 16- through 26-year-old girls and women (Table 10). Study 7 also enrolled 313 16- through 26-year-old HIV-negative MSM. At Month 7, anti-HPV GMT ratios for MSM relative to HM ranged from 0.6 to 0.8, depending on HPV type. The GMT ratios for MSM relative to HM were generally similar to those previously observed in clinical trials with GARDASIL.</p><p>&nbsp;</p><p><strong>Table 10: Comparison of Immune Responses (Based on cLIA) between the PPI* Populations of 16- through 26-Year-Old Girls and Women and 16- through 26-Year-Old Boys and Men Self-Identified as Heterosexual (HM) for All GARDASIL&nbsp;9 Vaccine HPV Types (Study 7)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Population</strong></p></td><td><p><strong>N<sup>&dagger;</sup></strong></p></td><td><p><strong>n<sup>&Dagger;</sup></strong></p></td><td><p><strong>GMT<br />mMU<sup>&sect;</sup>/mL</strong></p></td><td style="vertical-align:top"><p><strong>GMT Ratio relative to 16- through 26-year-old girls and women</strong></p><p><strong>(95% CI)<sup>&para;</sup></strong></p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 6</strong></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old HM</p></td><td style="vertical-align:top"><p>1103</p></td><td style="vertical-align:top"><p>847</p></td><td style="vertical-align:top"><p>782.0</p></td><td style="vertical-align:top"><p>1.11 (1.02, 1.21)</p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old girls and women</p></td><td><p>1099</p></td><td><p>708</p></td><td><p>703.9</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 11</strong></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old HM</p></td><td style="vertical-align:top"><p>1103</p></td><td><p>851</p></td><td><p>616.7</p></td><td style="vertical-align:top"><p>1.09 (1.00, 1.19)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>1099</p></td><td><p>712</p></td><td><p>564.9</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 16</strong></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old HM</p></td><td style="vertical-align:top"><p>1103</p></td><td><p>899</p></td><td><p>3346.0</p></td><td style="vertical-align:top"><p>1.20 (1.10, 1.30)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>1099</p></td><td><p>781</p></td><td><p>2788.3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 18</strong></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old HM</p></td><td style="vertical-align:top"><p>1103</p></td><td><p>906</p></td><td><p>808.2</p></td><td style="vertical-align:top"><p>1.19 (1.08, 1.31)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>1099</p></td><td><p>831</p></td><td><p>679.8</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 31</strong></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old HM</p></td><td style="vertical-align:top"><p>1103</p></td><td><p>908</p></td><td><p>708.5</p></td><td style="vertical-align:top"><p>1.24 (1.13, 1.37)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>1099</p></td><td><p>826</p></td><td><p>570.1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 33</strong></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old HM</p></td><td style="vertical-align:top"><p>1103</p></td><td><p>901</p></td><td><p>384.8</p></td><td style="vertical-align:top"><p>1.19 (1.10, 1.30)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>1099</p></td><td><p>853</p></td><td><p>322.0</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 45</strong></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old HM</p></td><td style="vertical-align:top"><p>1103</p></td><td><p>909</p></td><td><p>235.6</p></td><td style="vertical-align:top"><p>1.27 (1.14, 1.41)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>1099</p></td><td><p>871</p></td><td><p>185.7</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 52</strong></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old HM</p></td><td style="vertical-align:top"><p>1103</p></td><td><p>907</p></td><td><p>386.8</p></td><td style="vertical-align:top"><p>1.15 (1.05, 1.26)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>1099</p></td><td><p>849</p></td><td><p>335.2</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 58</strong></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old HM</p></td><td style="vertical-align:top"><p>1103</p></td><td><p>897</p></td><td><p>509.8</p></td><td style="vertical-align:top"><p>1.25 (1.14, 1.36)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>1099</p></td><td><p>839</p></td><td><p>409.3</p></td><td style="vertical-align:top"><p>1</p></td></tr></tbody></table><p>*The PPI population consisted of individuals who received all three vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, and were seronegative to the relevant HPV type(s) (types 6, 11, 16, 18, 31, 33, 45, 52, and 58) prior to dose 1. The data are from Study 7 (NCT01651949).</p><p><sup>&dagger;</sup>Number of individuals randomized to the respective vaccination group who received at least one injection</p><p><sup>&Dagger;</sup>Number of individuals contributing to the analysis</p><p><sup>&sect;</sup>mMU=milli-Merck Units</p><p><sup>&para;</sup>Demonstration of non-inferiority required that the lower bound of the 95% CI of the GMT ratio be greater than 0.67</p><p>cLIA=competitive Luminex Immunoassay</p><p>CI=Confidence Interval</p><p>GMT=Geometric Mean Titer</p><p>&nbsp;</p><p>Study Supporting the Effectiveness of GARDASIL&nbsp;9 against Vaccine HPV Types in 27- through 45-Year-Old Women</p><p>Effectiveness of GARDASIL&nbsp;9 against persistent infection and disease related to vaccine HPV types in 27- through 45-year-old women was supported by immunobridging comparisons conducted in the PPI population in Study 9. In Study 9, the GMT ratios of anti-HPV responses at Month&nbsp;7 among 27- through 45-year-old women relative to anti-HPV responses among 16- through 26-year-old girls and women met the success criteria of having the lower bound of the 95% CI of the GMT ratios greater than 0.50 for HPV 16, 18, 31, 33, 45, 52, and 58 (Table 11).</p><p>&nbsp;</p><p><strong>Table 11: Comparison of Immune Responses (Based on cLIA) Between the PPI* Populations of 27- through 45 Year-Old Women and 16- through 26-Year-Old Girls and Women for GARDASIL&nbsp;9 Vaccine HPV Types (Study 9)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Population</strong></p></td><td><p><strong>N<sup>&dagger;</sup></strong></p></td><td><p><strong>n<sup>&Dagger;</sup></strong></p></td><td><p><strong>GMT<br />mMU<sup>&sect;</sup>/mL</strong></p></td><td style="vertical-align:top"><p><strong>GMT Ratio relative to 16-through 26-year-old girls and women</strong></p><p><strong>(95% CI)<sup>&para;</sup></strong></p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 6</strong></p></td></tr><tr><td style="vertical-align:top"><p>27- through 45-year-old women</p></td><td style="vertical-align:top"><p>640</p></td><td style="vertical-align:top"><p>448</p></td><td style="vertical-align:top"><p>638.4</p></td><td style="vertical-align:top"><p>N.D<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old girls and women</p></td><td><p>570</p></td><td><p>421</p></td><td><p>787.8</p></td><td style="vertical-align:top"><p>N.D<sup>#</sup></p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 11</strong></p></td></tr><tr><td style="vertical-align:top"><p>27- through 45-year-old women</p></td><td style="vertical-align:top"><p>640</p></td><td style="vertical-align:top"><p>448</p></td><td style="vertical-align:top"><p>453.5</p></td><td style="vertical-align:top"><p>N.D<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old girls and women</p></td><td><p>570</p></td><td><p>421</p></td><td><p>598.7</p></td><td style="vertical-align:top"><p>N.D<sup>#</sup></p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 16</strong></p></td></tr><tr><td style="vertical-align:top"><p>27- through 45-year-old women</p></td><td style="vertical-align:top"><p>640</p></td><td style="vertical-align:top"><p>448</p></td><td style="vertical-align:top"><p>2,147.5</p></td><td style="vertical-align:top"><p>0.70 (0.63, 0.77)</p></td></tr><tr><td style="vertical-align:top"><p>16- through 26-year-old girls and women</p></td><td><p>570</p></td><td><p>436</p></td><td><p>3,075.8</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 18</strong></p></td></tr><tr><td style="vertical-align:top"><p>27- through 45-year-old women</p></td><td style="vertical-align:top"><p>640</p></td><td><p>471</p></td><td><p>532.1</p></td><td style="vertical-align:top"><p>0.71 (0.64, 0.80)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>570</p></td><td><p>421</p></td><td><p>744.5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 31</strong></p></td></tr><tr><td style="vertical-align:top"><p>27- through 45-year-old women</p></td><td style="vertical-align:top"><p>640</p></td><td><p>488</p></td><td><p>395.7</p></td><td style="vertical-align:top"><p>0.66 (0.60, 0.74)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>570</p></td><td><p>447</p></td><td><p>596.1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 33</strong></p></td></tr><tr><td style="vertical-align:top"><p>27- through 45-year-old women</p></td><td style="vertical-align:top"><p>640</p></td><td><p>493</p></td><td><p>259.0</p></td><td style="vertical-align:top"><p>0.73 (0.67, 0.80)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>570</p></td><td><p>457</p></td><td><p>354.5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 45</strong></p></td></tr><tr><td style="vertical-align:top"><p>27- through 45-year-old women</p></td><td style="vertical-align:top"><p>640</p></td><td><p>515</p></td><td><p>145.6</p></td><td style="vertical-align:top"><p>0.68 (0.60, 0.76)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>570</p></td><td><p>470</p></td><td><p>214.9</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 52</strong></p></td></tr><tr><td style="vertical-align:top"><p>27- through 45-year-old women</p></td><td style="vertical-align:top"><p>640</p></td><td><p>496</p></td><td><p>244.7</p></td><td style="vertical-align:top"><p>0.71 (0.64, 0.78)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>570</p></td><td><p>456</p></td><td><p>346.5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 58</strong></p></td></tr><tr><td style="vertical-align:top"><p>27- through 45-year-old women</p></td><td style="vertical-align:top"><p>640</p></td><td><p>478</p></td><td><p>296.4</p></td><td style="vertical-align:top"><p>0.69 (0.63, 0.76)</p></td></tr><tr><td><p>16- through 26-year-old girls and women</p></td><td><p>570</p></td><td><p>451</p></td><td><p>428.0</p></td><td style="vertical-align:top"><p>1</p></td></tr></tbody></table><p>*The PPI population consisted of individuals who received all 3 vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, and were seronegative to the relevant HPV type(s) (types 16, 18, 31, 33, 45, 52, and 58) prior to dose 1. The data are from Study 9 (NCT03158220).</p><p><sup>&dagger;</sup>Number of individuals randomized to the respective vaccination group who received at least 1 injection</p><p><sup>&Dagger;</sup>Number of individuals contributing to the analysis</p><p><sup>&sect;</sup>mMU=milli-Merck Units</p><p><sup>&para;</sup>Immunobridging required that the lower bound of the 95% CI of the GMT ratio be greater than 0.50</p><p><sup>#</sup>N.D=Not Determined. GMT ratios were not calculated because immunobridging comparison was not specified in the study protocol for HPV types 6 and 11.</p><p>cLIA=Competitive Luminex Immunoassay</p><p>CI=Confidence Interval</p><p>GMT=Geometric Mean Titers</p><p>&nbsp;</p><p>Immune Response to GARDASIL&nbsp;9 across All Clinical Trials</p><p>Across all clinical trials, at least 99.2% of individuals included in the analyses for each of the nine vaccine HPV types became seropositive by Month 7. Anti-HPV GMTs at Month 7 among 9- through 15-year-old girls and boys and 16- through 26-year-old boys and men were comparable to anti-HPV responses among 16- through 26-year-old girls and women in the combined database of immunogenicity studies for GARDASIL&nbsp;9.</p><p>&nbsp;</p><p>Persistence of Immune Response to GARDASIL&nbsp;9</p><p>In an extension study of individuals in Study 2, among girls and boys 9 through 15 years of age at enrollment (range of 494 to 525 subjects with evaluable data across HPV types) and followed for 10 years post dose 3, anti-HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 GMTs as measured by cLIA were decreased compared with corresponding values at one-month post-dose 3. The proportion of seropositive subjects ranged from 99.6% to 100% at one month post-dose 3 and from 81.3% to 97.7% at 10 years post-dose 3, depending on HPV type.</p><p>&nbsp;</p><p>Administration of GARDASIL&nbsp;9 to Individuals Previously Vaccinated with GARDASIL</p><p>Study 4 evaluated the immunogenicity of 3 doses of GARDASIL&nbsp;9 in 921 girls and women (12 through 26 years of age) who had previously been vaccinated with 3 doses of GARDASIL. Prior to enrollment in the study, over 99% of subjects had received three injections of GARDASIL within a one year period. The time interval between the last injection of GARDASIL and the first injection of GARDASIL&nbsp;9 ranged from approximately 12 to 36 months.</p><p>Seropositivity to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in the per protocol population ranged from 98.3 to 100% by Month 7 in individuals who received GARDASIL&nbsp;9. The anti-HPV 31, 33, 45, 52 and 58 GMTs for the population previously vaccinated with GARDASIL were 25-63% of the GMTs in the combined populations from Studies 1, 2, 3, and 5, who had not previously received GARDASIL, although the clinical relevance of these differences is unknown. Efficacy of GARDASIL&nbsp;9 in preventing infection and disease related to HPV Types 31, 33, 45, 52, and 58 in individuals previously vaccinated with GARDASIL has not been assessed.</p><p>&nbsp;</p><p>Concomitant Use of Hormonal Contraceptives</p><p>Among 7,269 female recipients of GARDASIL&nbsp;9 (16 through 26 years of age), 60.2% used hormonal contraceptives during the vaccination period of clinical studies 1 and 2. Use of hormonal contraceptives did not appear to affect the type specific immune responses to GARDASIL&nbsp;9.</p><p>&nbsp;</p><p><strong>Immune Responses to GARDASIL&nbsp;9 Using a 2-Dose Regimen in Individuals 9 through 14 Years of Age</strong></p><p>Effectiveness of GARDASIL&nbsp;9 against persistent infection and disease related to vaccine HPV types in 9- through 14-year-old girls and boys who received a 2-dose regimen was inferred from non-inferiority comparison conducted in the PPI population in Study 8 of GMTs following vaccination with GARDASIL&nbsp;9 among 9- through 14-year-old girls and boys who received a 2-dose regimen (at 0, 6 months or 0, 12 months) with those among 16- through 26-year-old girls and women who received a 3-dose regimen (at 0, 2, 6 months). Anti-HPV GMTs at one month after the last dose among 9- through 14-year-old girls and boys who received 2 doses of GARDASIL 9 were non-inferior to anti-HPV GMTs among 16- through 26-year-old girls and women who received 3 doses of GARDASIL&nbsp;9 (Table 12).</p><p>One month following the last dose of the assigned regimen, between 97.9% and 100% of subjects across all groups became seropositive for antibodies against the 9 vaccine HPV types (Table 12).</p><p>In the same study, in girls and boys 9 through 14 years old, GMTs at one month after the last vaccine dose were numerically lower for some vaccine types after a 2-dose schedule than in girls 9 through 14 years old after a 3-dose schedule (HPV types 18, 31, 45, and 52 after 0, 6 months and HPV type 45 after 0, 12 months; Table 12). The clinical relevance of these findings is unknown.</p><p>Duration of immunity of a 2-dose schedule of GARDASIL&nbsp;9 has not been established.</p><p><strong>Table 12: Summary of Anti-HPV cLIA Geometric Mean Titers in the PPI* Population at One Month After the Last Vaccine Dose Among Subjects Who Received 2 Doses<sup>&dagger;</sup> or 3 Doses<sup>&dagger;</sup> of GARDASIL&nbsp;9 (Study 8)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td><p><strong>Population (Regimen)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>n</strong></p></td><td><p><strong>GMT</strong></p><p><strong>mMU</strong><sup>&Dagger;</sup><strong>/mL</strong></p></td><td style="vertical-align:top"><p><strong>GMT Ratio relative to 3-dose regimen in 16- through 26-year-old girls and women</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 6</strong></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>258</p></td><td><p>1657.9</p></td><td style="vertical-align:top"><p>2.15 (1.83, 2.53)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old boys (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>263</p></td><td><p>1557.4</p></td><td style="vertical-align:top"><p>2.02 (1.73, 2.36)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls and boys (0, 12)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>257</p></td><td><p>2678.8</p></td><td style="vertical-align:top"><p>3.47 (2.93, 4.11)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>254</p></td><td><p>1496.1</p></td><td style="vertical-align:top"><p>1.94 (1.65, 2.29)<sup>&para;</sup></p></td></tr><tr><td><p>16- to 26-year-old women (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>314</p></td><td><p>238</p></td><td><p>770.9</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 11</strong></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>258</p></td><td><p>1388.9</p></td><td style="vertical-align:top"><p>2.39 (2.03, 2.82)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old boys (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>264</p></td><td><p>1423.9</p></td><td style="vertical-align:top"><p>2.45 (2.09, 2.88)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls and boys (0, 12)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>257</p></td><td><p>2941.8</p></td><td style="vertical-align:top"><p>5.07 (4.32, 5.94)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>254</p></td><td><p>1306.3</p></td><td style="vertical-align:top"><p>2.25 (1.90, 2.66)<sup>&para;</sup></p></td></tr><tr><td><p>16- to 26-year-old women (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>314</p></td><td><p>238</p></td><td><p>580.5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 16</strong></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>272</p></td><td><p>8004.9</p></td><td style="vertical-align:top"><p>2.54 (2.14, 3.00)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old boys (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>273</p></td><td><p>8474.8</p></td><td style="vertical-align:top"><p>2.69 (2.29, 3.15)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls and boys (0, 12)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>264</p></td><td><p>14329.3</p></td><td style="vertical-align:top"><p>4.54 (3.84, 5.37)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>269</p></td><td><p>6996.0</p></td><td style="vertical-align:top"><p>2.22 (1.89, 2.61)<sup>&para;</sup></p></td></tr><tr><td><p>16- to 26-year-old women (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>314</p></td><td><p>249</p></td><td><p>3154.0</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 18</strong></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>272</p></td><td><p>1872.8</p></td><td style="vertical-align:top"><p>2.46 (2.05, 2.96)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old boys (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>272</p></td><td><p>1860.9</p></td><td style="vertical-align:top"><p>2.44 (2.04, 2.92)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls and boys (0, 12)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>266</p></td><td><p>2810.4</p></td><td style="vertical-align:top"><p>3.69 (3.06, 4.45)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>270</p></td><td><p>2049.3</p></td><td style="vertical-align:top"><p>2.69 (2.24, 3.24)<sup>&para;</sup></p></td></tr><tr><td><p>16- to 26-year-old women (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>314</p></td><td><p>267</p></td><td><p>761.5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 31</strong></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>272</p></td><td><p>1436.3</p></td><td style="vertical-align:top"><p>2.51 (2.10, 3.00)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old boys (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>271</p></td><td><p>1498.2</p></td><td style="vertical-align:top"><p>2.62 (2.20, 3.12)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls and boys (0, 12)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>268</p></td><td><p>2117.5</p></td><td style="vertical-align:top"><p>3.70 (3.08, 4.45)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>271</p></td><td><p>1748.3</p></td><td style="vertical-align:top"><p>3.06 (2.54, 3.67)<sup>&para;</sup></p></td></tr><tr><td><p>16- to 26-year-old women (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>314</p></td><td><p>264</p></td><td><p>572.1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 33</strong></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>273</p></td><td><p>1030.0</p></td><td style="vertical-align:top"><p>2.96 (2.50, 3.50)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old boys (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>271</p></td><td><p>1040.0</p></td><td style="vertical-align:top"><p>2.99 (2.55, 3.50)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls and boys (0, 12)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>269</p></td><td><p>2197.5</p></td><td style="vertical-align:top"><p>6.31 (5.36, 7.43)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>275</p></td><td><p>796.4</p></td><td style="vertical-align:top"><p>2.29 (1.95, 2.68)<sup> &para;</sup></p></td></tr><tr><td><p>16- to 26-year-old women (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>314</p></td><td><p>279</p></td><td><p>348.1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 45</strong></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>274</p></td><td><p>357.6</p></td><td style="vertical-align:top"><p>1.67 (1.38, 2.03)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old boys (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>273</p></td><td><p>352.3</p></td><td style="vertical-align:top"><p>1.65 (1.37, 1.99)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls and boys (0, 12)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>268</p></td><td><p>417.7</p></td><td style="vertical-align:top"><p>1.96 (1.61, 2.37)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>275</p></td><td><p>661.7</p></td><td style="vertical-align:top"><p>3.10 (2.54, 3.77)<sup>&para;</sup></p></td></tr><tr><td><p>16- to 26-year-old women (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>314</p></td><td><p>280</p></td><td><p>213.6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 52</strong></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>272</p></td><td><p>581.1</p></td><td style="vertical-align:top"><p>1.60 (1.36, 1.87)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old boys (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>273</p></td><td><p>640.4</p></td><td style="vertical-align:top"><p>1.76 (1.51, 2.05)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls and boys (0, 12)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>268</p></td><td><p>1123.4</p></td><td style="vertical-align:top"><p>3.08 (2.64, 3.61)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>275</p></td><td><p>909.9</p></td><td style="vertical-align:top"><p>2.50 (2.12, 2.95)<sup>&para;</sup></p></td></tr><tr><td><p>16- to 26-year-old women (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>314</p></td><td><p>271</p></td><td><p>364.2</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="5"><p><strong>Anti-HPV 58</strong></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>270</p></td><td><p>1251.2</p></td><td style="vertical-align:top"><p>2.55 (2.15, 3.01)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old boys (0, 6)<sup>&dagger;</sup></p></td><td><p>301</p></td><td><p>270</p></td><td><p>1325.7</p></td><td style="vertical-align:top"><p>2.70 (2.30, 3.16)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls and boys (0, 12)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>265</p></td><td><p>2444.6</p></td><td style="vertical-align:top"><p>4.98 (4.23, 5.86)<sup>&sect;</sup></p></td></tr><tr><td><p>9- to 14-year-old girls (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>300</p></td><td><p>273</p></td><td><p>1229.3</p></td><td style="vertical-align:top"><p>2.50 (2.11, 2.97)<sup>&para;</sup></p></td></tr><tr><td><p>16- to 26-year-old women (0, 2, 6)<sup>&dagger;</sup></p></td><td><p>314</p></td><td><p>261</p></td><td><p>491.1</p></td><td style="vertical-align:top"><p>1</p></td></tr></tbody></table><p>*The PPI population consisted of individuals who received all assigned vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the last vaccination dose and blood collection for immunogenicity assessment, and were seronegative to the relevant HPV type(s) (types 6, 11, 16, 18, 31, 33, 45, 52, and 58) prior to dose 1.</p><p><sup>&dagger;</sup>2-dose regimen (0, 6): vaccination at Day 1 and Month 6; 2-dose regimen (0, 12): vaccination at Day 1 and Month&nbsp;12; 3-dose regimen (0, 2, 6): vaccination at Day 1, Month 2, and Month&nbsp;6. The data are from Study 8 (NCT01984697).</p><p><sup>&Dagger;</sup>mMU=milli-Merck Units</p><p><sup>&sect;</sup>Demonstration of non-inferiority required that the lower bound of the 95% CI of the GMT ratio be greater than 0.67</p><p><sup>&para;</sup>Exploratory analysis; criterion for non-inferiority was not pre-specified</p><p>N = Number of individuals randomized to the respective vaccination group who received at least 1 injection</p><p>n = Number of individuals contributing to the analysis</p><p>CI=Confidence Interval</p><p>cLIA=competitive Luminex Immunoassay</p><p>GMT=Geometric Mean Titer</p><p>&nbsp;</p><p><strong>Studies with Menactra and Adacel</strong></p><p>In Study 5, the safety and immunogenicity of co-administration of GARDASIL&nbsp;9 with Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] and Adacel [Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)] (same visit, injections at separate sites) were evaluated in 1,237 boys and girls 11 through 15 years of age at enrollment.</p><p>One group received GARDASIL&nbsp;9 in one limb and both Menactra and Adacel, as separate injections, in the opposite limb concomitantly on Day 1 (n = 619). The second group received the first dose of GARDASIL&nbsp;9 on Day 1 in one limb then Menactra and Adacel, as separate injections, at Month 1 in the opposite limb (n = 618). Subjects in both vaccination groups received the second dose of GARDASIL&nbsp;9 at Month 2 and the third dose at Month 6. Immunogenicity was assessed for all vaccines one month post vaccination (one dose for Menactra and Adacel and three doses for GARDASIL&nbsp;9).</p><p>Assessments of post-vaccination immune responses included type-specific antibody GMTs for each of the vaccine HPV types at four weeks following the last dose of GARDASIL&nbsp;9; GMTs for anti-filamentous hemagglutinin, anti-pertactin, and anti-fimbrial antibodies at four weeks following Adacel; percentage of subjects with anti-tetanus toxin and anti-diphtheria toxin antibody concentrations &ge;0.1 IU/mL at four weeks following Adacel; and percentage of subjects with &ge;4-fold rise from pre-vaccination baseline in antibody titers against <em>N. meningitidis</em> serogroups A, C, Y, and W-135 at four weeks following Menactra. Based on these measures, concomitant administration of GARDASIL&nbsp;9 with Menactra and Adacel did not interfere with the antibody responses to any of the vaccines when compared with non-concomitant administration of GARDASIL&nbsp;9 with Menactra and Adacel.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, Impairment&nbsp;of&nbsp;Fertility</strong></p><p>Gardasil&nbsp;9 has not been evaluated for the potential to cause carcinogenicity, genotoxicity or impairment of male fertility. GARDASIL&nbsp;9 administered to female rats had no effects on fertility <em>[see Fertility, Pregnancy and Lactation (4.6)]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</strong></p><p>&nbsp;</p><p>Amorphous aluminum hydroxyphosphate sulfate adjuvant (500 &mu;g aluminum content)</p><p>Sodium chloride (9.56mg)</p><p>L-histidine (0.78mg)</p><p>Polysorbate 80 (50 &mu;g)</p><p>Sodium borate (35 &mu;g)</p><p>Water for injections (QS)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gardasil&nbsp;9 suspension for injection </u><u>in a pre-filled syringe:</u></p><p>&nbsp;</p><p>Store refrigerated at (2 &deg;C &ndash; 8 &deg;C).</p><p>&nbsp;</p><p>Do not freeze. Protect from light.</p><p>&nbsp;</p><p>Gardasil&nbsp;9 should be administered as soon as possible after being removed from the refrigerator.</p><p>&nbsp;</p><p>Gardasil&nbsp;9 can be administered provided total (cumulative multiple excursion) time out of refrigeration (at temperatures between 8&deg;C and 25&deg;C) does not exceed 72 hours. Cumulative multiple excursions between 0&deg;C and 2&deg;C are also permitted as long as the total time between 0&deg;C and 2&deg;C does not exceed 72 hours. These are not, however, recommendations for storage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gardasil 9 is supplied in syringes</u></p><p>Carton of one 0.5-mL single-dose prefilled Luer Lock syringes with tip cap with needle.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gardasil&nbsp;9 suspension for injection </u><u>in a pre-filled syringe:</u></p><p><em>&nbsp;</em></p><p>Any unused vaccine or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder & Manufacturer: 
Merck Sharp & Dohme  LLC
770 Sumneytown Pike,
West Point, Pennsylvania 19486, USA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>